Interstitial fibrosis and growth factors. by Lasky, J A & Brody, A R
Interstitial Fibrosis and Growth Factors
Joseph A. Lasky1 and Arnold R. Brody2
'Section of Pulmonary Diseases, Critical Care and Environmental Medicine, Department of Medicine, and the Lung Biology Program, Tulane
University Medical Center, New Orleans, Louisiana, USA; 2Departments of Pathology and Environmental Health Sciences, and the Lung
Biology Program, Tulane University Medical Center, New Orleans, Louisiana, USA
Interstitial pulmonary fibrosis (IPF) is scarring of the lung caused by a variety of inhaled agents
including mineral particles, organic dusts, and oxidant gases. The disease afflicts millions of
individuals worldwide, and there are no effective therapeutic approaches. A major reason for this
lack of useful treatments is that few of the molecular mechanisms of disease have been defined
sufficiently to design appropriate targets for therapy. Our laboratory has focused on the molecular
mechanisms through which three selected peptide growth factors could play a role in the
development of IPF. Hundreds of growth factors and cytokines could be involved in the complex
disease process. We are studying platelet-derived growth factor because it is the most potent
mesenchymal cell mitogen yet described, transforming growth factor beta because it is a powerful
inducer of extracellular matrix (scar tissue) components by mesenchymal cells, and tumor necrosis
factor alpha because it is a pleiotropic cytokine that we and others have shown is essential for the
development of IPF in animal models. This review describes some of the evidence from studies in
humans, in animal models, and in vitro, that supports the growth factor hypothesis. The use of
modern molecular and transgenic technologies could elucidate those targets that will allow
effective therapeutic approaches. Key words: particle inhalation, peptide growth factors, platelet-
derived growth factor, pulmonary fibrosis, transforming growth factor beta, tumor necrosis factor.
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A great deal ofknowledge has been amassed
over the past three decades on epidemiologic
(1), clinical (2), pathologic (3), and biologic
details (4) ofinterstitial pulmonary fibrosis
(IPF). IPF by definition, includes idiopathic
disease for which the cause is not known, the
pneumoconioses (particle-induced disease),
and a number of other inflammatory and
immunologically mediated interstitial
processes. Despite this information, it is obvi-
ous that our understanding ofdisease patho-
genesis is insufficient inasmuch as there are no
effective therapeutic modalities. It is our goal
in this article to present a portion ofwhat is
known about IPF but more about what is not
known. The key to future success in develop-
ing useful treatment strategies for IPF will be
to focus on the mediators ofinflammation,
cell proliferation, and extracellular matrix pro-
duction, the three major features ofthe disease
process that culminate in the clinical features
of IPF. Before any one of these complex
processes can be ameliorated or blocked, we
must develop a more complete understanding
of the fundamental molecular mechanisms
that drivedevelopment ofdisease.
The need to investigate the pathogenesis
ofpulmonary fibrosis is imperative because
the clinical outcome for the vast majority of
patients with IPF remains poor. Published
statistics indicate that our lack ofability to
intervene in the fibrotic process leads to pre-
mature death. In a retrospective study
published 20 years ago, Carrington et al. (5)
reported on the natural history and treated
course of 53 patients with usual interstitial
pneumonitis (UIP), and found that only 50%
remained alive after 5 years and 18% after 10
years following their diagnosis. More recent
5- and 10-year Kaplan Meier survival analyses
figures were 53 and 20%, respectively, in 85
subjects with UIP followed by the United
States Armed Forces Institute between 1974
and 1993 according to Travis et al. (6). The
lack of improvement in IPF mortality over
the 20-year interval between the Carrington
and Travis reports clearly indicates that cur-
rentlyemployed medical regimens are ofmar-
ginal use. The dismal response to currently
available therapies underscores the need to
understand the pathobiology ofpulmonary
fibrosis.
An important cause of interstitial lung
disease (ILD) is inhalation of fibrogenic
agents encountered in theworkplace or in the
environment (7). Environmental entities
known to cause pulmonary fibrosis include
organic dusts containing protein antigens and
inorganic dusts (e.g., asbestos, silica, metals).
Inhalation ofeach ofthese substances gener-
ates lung damage that with chronic exposure
leads to fibrosis. Even though in 30-40% of
subjects with fibrotic lung disease, the cause
remains unknown (idiopathic) (8), there is
evidence to suggest that in many of these,
environmental exposure may contribute to
disease pathogenesis. Metal and wood dust
exposures have been found to be an indepen-
dent risk factor for IPF, with estimates that
such exposures may account for 16-23% of
the cases (9). There are also reports that in
some arid regions ofthe world, including the
southwestern United States, nonoccupational
exposure to aluminum silicates results in
fibrogenic lung disease (10). In addition, a
few studies suggest that cigarette smoke may
contribute to the pathogenesis ofIPF (11).
Even though the pathologic changes
induced by the individual fibrotic agents have
recognizable differences, they share a number
ofcommon features, including inflammation,
mesenchymal cell proliferation, and extracel-
lular matrix deposition. These features are
induced byavariety ofagents, suggesting that
different types oflung injury can converge
into common inflammation and repair path-
ways. Within this context, it is essential to
understand the nature ofthe molecules that
mediate the initiation and progression ofpul-
monary fibrosis induced by environmental
agents. Many potential mediators have been
identified at increased levels in the lungs of
patients with occupational or environmental
lung disease and in animal models ofdisease
induced by fibrotic agents. We have proposed
that certain growth factors, cytokines, and
inflammatory mediators are likely to be
involved in fibroproliferative lung disease
regardless ofthe etiology. The challenge is to
determine which ofthese mediators are cen-
tral to the development of fibrotic lesions
after inhalation ofenvironmental toxicants.
Clinical Concepts Associated
with IPF
Several texts define the clinical concepts
associated with IPF (4). However, this review
is not the place to dwell on the clinical fea-
tures, which have a solid base ofinformation
that has changed little over the years. Thus,
based upon detailed descriptions by
Katzenstein et al. (3), it is understood that
IPF exhibits its earliest clinical manifestations
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as increased accumulations ofinflammatory
and immune effector cells within the alveolar
walls and airspaces (12). These changes have
been assessed by lung lavage and biopsy pro-
cedures that demonstrate dramatic shifts in
the percentages ofthe cells normally inhabit-
ing the lung parenchyma. For example, a
normal lavage of the human lung yields a
population ofabout 95% macrophages (gen-
erally differentiated), 4% neutrophils, and
few lymphocytes. Individuals with IPF can
have more than 50% neutrophils, or lym-
phocytes in the lavage, and this corresponds,
respectively, to a higher or lower risk of
developing progressive interstitial fibrosis
(13). Individuals with large numbers ofinfil-
trating lymphocytes appear more likely to
respond to treatment with prednisone and/or
immune-suppressive drugs (14). Regardless
ofthe etiology ofthe inflammation, ifit per-
sists, diffuse alveolar wall thickening and
fibrosis is the result. This causes a stifflung
with concomitant abnormalities of gas
exchange as the alveolar-capillary mem-
branes widen from increased deposition of
extracellular matrix, as the microvascular bed
is destroyed by the fibrotic process, and as
abnormalities in ventilation-perfusion
matching occur (15). As the fibrogenesis pro-
gresses, scarring becomes more obvious by
radiographic studies, and the disease tends to
be even more refractory to successful thera-
peutic intervention (16).
The diffuse ILDs that develop according
to this common scenario, greatly simplified
above, generally are classified into two large
groups, those with known and those with
unknown causes. Some ofthe more common
causes of IPF are inorganic dusts such as
asbestos and silica, organic dusts that cause
hypersensitivity pneumonitis, and gases like
oxygen, ozone, and sulfur dioxide. Infectious
microorganisms, including several viruses,
bacteria, and fungi are known to cause IPF.
There also are a number of fibrogenic
processes for which the etiology remains
unknown. Several of the more familiar of
these are sarcoidosis, collagen-vascular-
associated fibrosis, alveolar proteinosis, and
bydefinition, idiopathic pulmonary fibrosis.
The ultimate goal of those studying the
diseases noted previously is to develop effec-
tive therapeutic strategies for the treatment
of IPF. To do so will require a detailed
understanding ofthe molecular mechanisms
that control inflammatory cell migration, cell
proliferation, and production ofextracellular
matrix components. These are the three key
features controlling fibrogenesis, but each
one is highly complex and must be reduced
to concepts that can be manipulated effec-
tively. For example, ifthe alveolar epithelium
has been injured (e.g., by asbestos, a virus, or
an oxidant gas), inflammatory cells are
recruited from the circulation and/or
surrounding tissues. Which ofthe numerous
chemotactic cytokines and attachment pro-
teins play essential roles in this central
process? The injured epithelium must repair
by proliferation and differentiation, while
mesenchymal and endothelial cells of the
interstitial compartment proceed through
multiple rounds ofcell division. Dozens of
mitogenic factors could control this phase of
alveolar repair, which in itself is part ofthe
pathway to fibrosis. Finally, with continuing
injury and/or inflammation, the expanded
mesenchymal cell population synthesizes and
secretes multiple components ofthe extracel-
lular matrix. Which ofthese is essential to
the production of the scarring that is incom-
patible with normal lung functions? How is
the balance maintained (or lost) among the
many types ofcollagen molecules and the
enzymes designed to degrade them (17)?
Which ofthe manypeptides that induce pro-
duction ofextracellular matrix components
are critical in the progression ofIPF? These
three key features, inflammation, prolifera-
tion, and matrix production, are inextricably
intertwined. The inflammatory cells are a
major source of the mitogens and matrix-
inducing peptides (18). The proliferating
epithelium has been identified as a producer
ofthese molecules as well (19,20). In addi-
tion, the mesenchymal cells, fibroblasts and
myofibroblasts, not only release matrix but
also produce significant amounts ofthe very
molecules that control their proliferation and
synthesis of the connective tissue compo-
nents (21-23). Thus, there are numerous tar-
gets at which therapeutic modalities could be
directed. Disruption ofany one ofthe key
pathways could provide potential benefits.
Some of these approaches currently are in
clinical trials. For example, cyclophos-
phamide appears to decrease lymphocytes in
the lung (24) and azathioprine suppresses
cellular immunity (25). Colchicine and
methotrexate appear to reduce inflammation
by blocking some cell migration and perhaps
by reducing elaboration of extracellular
matrix (26). Penicillamine appears to prevent
cross-linking of collagen (27) and cyclo-
sporine suppresses T-cell function (28). All
ofthese are blunt tools with little evidence of
success in most cases. The next generation of
therapeutic agents, therefore, must be pre-
cisely targeted at the molecular pathways that
control the three keyfeatures ofdisease.
It is impossible in this forum to even
touch upon all the molecular pathways that
are operative during fibrogenesis. At a recent
meeting ofthe American Thoracic Society,
numerous abstracts were directed toward a
more fundamental understanding of IPF.
Thus, the remainder ofthis article focuses on
one small aspect ofthe fibrogenic process,
i.e., the growth factor hypothesis. Even this
paradigm is far too extensive for complete
consideration here, we focus on approaches
to understanding the molecular mechanisms
through which three peptide growth factors
could be mediating, at least in part, the
pathogenesis ofthe fibroproliferative process
that leads to lung fibrosis. The three factors
considered here are tumor necrosis factor
alpha (TNF-a), platelet-derived growth
factors (PDGF), and transforming growth
factor beta (TGF-13).
Growth Factors
TumorNecrosis FactorAlpha
Inflammation is a consistent histopathologic
feature ofpulmonary fibrosis, though clearly
the magnitude ofinflammation and the char-
acter ofinflammatory cells vary depending on
the incitingetiologyofthe fibrosis (29). TNF-
a, so named because it was first identified as
an oncolytic factorfor tumors (30), is apotent
proinflammatory cytokine (31). TNF-a is
secreted as a 26-kDa membrane-bound gly-
copeptide that is cleaved by TNF-a convert-
ing enzyme to release a 17-kDa monomeric
peptide (32). Both free and membrane-bound
forms are biologically active. Soluble TNF-a
forms a homotrimer and induces receptor
multimerization at the cell surface (33). Two
TNF-a receptors have been identified, a
55-kDa receptor (TNFR1) and a 75-kDa
receptor (TNFR2), through which TNF-a
mediates its biologic responses (33). TNFR1
transduces proinflammatory and cytotoxic sig-
nals, whereas TNFR2 induces thymocyte pro-
liferation (34,35). Most cell types express both
TNF-a receptors (31).
The mechanism through which TNF-a
participates in the development ofpulmonary
fibrosis appears to be multifactorial, includ-
ing: induction ofinflammatory cell adhesion,
enhancement ofa procoagulant environment,
initiation of a cytokine cascade, immuno-
modulatory effects on lymphocytes, mito-
genic activity for mesenchymal cells,
regulation ofapoptosis, and regulation ofcol-
lagen synthesis and resorbtion (31). TNF-a is
able to recruit into the lung several cell types
such as eosinophils and platelets, and these
cells can release potent profibrotic mediators
(36). Platelet aggregation has been observed
in the pulmonary vasculature ofsubjects with
pulmonary fibrosis (37). Activation of
platelets leads to the release ofother profi-
brotic cytokines, including PDGF and
TGF-,I, on which we will elaborate in the
other two sections ofthis review. TNF-a has
also been shown in a coculture system to
induce adhesion of platelets to vascular
endothelium (38). Eosinophils are a rich
source ofinterleukin (IL)-5, and administra-
tion ofanti-TNF-a antibodies to mice in a
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bleomycin-induced model oflung fibrosis
results in diminished IL-5 mRNA expression
along with a decrease in lung eosinophils
(39). Investigators have confirmed a role for
eosinophil recruitment in the bleomycin
model of pulmonary fibrosis using both
anti-IL-5 antibodies and IL-5 knockout mice
(40). Proinflammatory effects ofTNF-a also
include induction ofother proinflammatory
cytokines such as IL-1 and macrophage
inflammatory protein la (MIP-la). TNF-a,
in combination with IL-6, stimulates
MIP-1a expression in leukocytes recovered
from lung lavage, and administration ofa sol-
uble TNF-oa receptor reduces MIP-la
expression in bleomycin-treated mouse lung
(41). TNF-a also induces IL-6 expression, its
cofactor for upregulating MIP-la (41).
In addition to recruitmentofinflammatory
cells that secrete mesenchymal cell mitogens,
TNF-a may act as a fibroblast mitogen
through a PDGF-dependent pathway (42).
Furthermore, TNF-a induces upregulation of
TGF-31 mRNA expression (43) and would
therefore be expected to upregulate collagen
transcription. However, under certain cir-
cumstances, TNF-a has been found to
decrease collagen transcription (44,45),
which could also conceivably occur via down-
regulation ofanother potent stimulator of
collagen expression, namely connective tissue
growth factor (CTGF) (46). On the other
hand, TNF-a in combination with IL-1 has
been shown to upregulate collagen transcrip-
tion in lung fibroblasts under serum-free con-
ditions (47). TNF-a also possesses activity
that favors dissolution of matrix through
induction of the collagenase metallopro-
teinase-1 (MMP-1) and gelatinase (48,49).
Blocking TNF-a clearly reduces the early
inflammation that ensues following lung
injury and thereby reduces fibrosis, yet the
net effect ofTNF-a on collagen accumula-
tion in the later stages offibrogenesis is not
yet known.
Animal models of pulmonary fibrosis
have been instrumental in establishing a role
for TNF-a in disease pathogenesis. These
models have provided insight into lung
fibrogenesis, and include the early time
points that are difficult to evaluate using
human lung specimens, as most patients
seek medical attention late in the course of
their disease after considerable lung function
has been lost (50). For example, bleomycin,
a profibrotic chemotherapeutic agent,
induces an increase in TNF-a mRNA
expression in a bleomycin-sensitive mouse
strain but not in a bleomycin-resistant strain
(51,52). Elevated levels ofbioactive TNF-a
have been detected in murine lung lavage
fluid after bleomycin administration (41).
Anti-TNF-a antibodies (53) and soluble
recombinant TNF-a receptors (37) abrogate
bleomycin-induced fibrosis. Moreover,
administration ofsoluble TNF-a receptors
results in a reduction of established
bleomycin-induced fibrosis (37). More recent
data show that double TNFR knockout mice
are resistant to bleomycin-induced fibrosis,
and thus define an essential role for TNF-a
receptors in the pathogenesis ofpulmonary
fibrosis (52). Another mechanism whereby
TNF-a may effect lung fibrosis is via induc-
tion ofapoptosis in inflammatory and other
lung cell types. Apoptosis is more prominent
in macrophages lavaged from the lungs ofa
bleomycin-sensitive strain than from the
lungs of a bleomycin-resistant strain and
double TNF-a receptor knockout mice (52).
A murine model ofsilica-induced lung
injury demonstrates an increase in TNF-a
mRNA (54) and lung lavage protein expres-
sion (55), which precedes subsequent fibrosis;
both are blocked by administration of
inhibitors ofreactive oxygen intermediates
(56). In situ hybridization has localized the
silica-induced TNF-a expression within
mononuclear cells located in alveolar spaces
and lymphoid nodules (57). C57BL/6 silica-
sensitive mice exhibit increased TNF-a
mRNA expression in total lung RNA follow-
ing silica exposure as well as increased
TNFR2 but not TNFR1 mRNA expression
after silica exposure (55,58). In contrast,
silica-resistant C3H/HeJ mice do not upregu-
late TNF-a ligand or receptor RNA expres-
sion in response to intratracheal instillation of
silica. Furthermore, TNF-a receptor double
knockout mice bredon asilica-sensitive strain
background do not develop fibrosis in
response to silica (58). These data provide
strong evidence for a significant role for
TNF-a in silica-induced pulmonary fibrosis.
Yet the role ofthe individual TNF-a recep-
tors in mediating lung fibrosis remains to
be darified.
Human alveolar macrophages exposed to
soot or asbestos fibers in vitro demonstrate a
significant increase in release ofTNF-a (59),
and administration ofcrocidolite asbestos
fibers to rats results in fibrosis, which is pre-
ceded by an increase in bronchoalveolar
lavage (BAL) fluid TNF-a expression (60).
These kinds ofstudies are useful for deter-
mining which cells secrete TNF-a in a quan-
titative way, but it is the experiments using
genetically altered mice that offer the most
hope for understanding the precise role of
TNF-a and other peptide factors in the
pathogenesis of IPF. For example, C57B116
mice develop asbestos-induced fibroprolifera-
tive lesions at the alveolar duct bifurcations,
the predominant site offiber deposition (61).
TNF-a expression was localized to macro-
phages and alveolar epithelial cells in this
murine model ofchrysotile asbestos-induced
fibrosis (20). However, J129 mice, which do
not develop macrophage infiltration or fibro-
proliferative lesions in response to asbestos, do
not increase their TNF-a expression, as
assessed by in situhybridization and immuno-
histochemistry (62). Moreover, double TNF-
a receptor knockout mice are protected from
the asbestos-induced fibrosis (20). Thus, there
is convincing evidence ofa critical role for
TNF-a in the pathogenesis ofthe inflamma-
tory and subsequent fibroproliferative
response in models ofpneumoconiosis.
Other animal models oflung fibrosis have
also demonstrated an increase in TNF-a
expression. These include Sendai virus-
induced peribronchiolar fibrosis in rats (63),
amiodarone-induced pulmonary fibrosis in
rats (64), and irradiation pneumonitis in
which TNF-a mRNA expression is elevated
following lung injury before development of
fibrosis in a radiation-sensitive mouse strain
but not in a resistant murine strain (65).
Animal models that involve TNF-a over-
expression in the lung have both confirmed
that TNF-a overexpression results in pul-
monary fibrosis and provided insight into the
mechanism ofTNF-a-mediated fibrosis.
Overexpression ofTNF-a specifically in lung
epithelial cells using the surfactant protein-C
promoter results in a mixed alveolitis with
neutrophils, monocytes and lymphocytes,
and thickened septal walls along with
increased hydroxyproline content as a mea-
sure ofcollagen accumulation (66). In agree-
ment with the above findings, TNF-a was
overexpressed for 7-10 days, using an adeno-
viral vector and resulting in murine lung
fibrosis in a study by Sime et al. (43). An
early inflammatory phase with neutrophils,
monocytes, and eosinophils is followed by a
fibrotic phase following administration of
TNF-ax using the adenoviral vector. TGF-, is
increased in this model, presumably because
ofTNF-a expression, a concept that will be
discussed further.
The "motheaten mouse" is a mutant that
develops pulmonary fibrosis with a promi-
nent pathologic feature of macrophage
inflammation. Serum levels ofTNF-a in
motheaten mice are elevated compared to
those in wild-type littermates. Furthermore,
lung macrophage production ofTNF-a in
response to lipopolysaccharide is increased in
motheaten mice, and TNF-a immunohisto-
chemical staining localizes the increased
TNF-a expression within macrophagelike
cells in lung tissue sections from motheaten
mice (67). Moreover, the severity of acute
lung injury is diminished in motheaten bone
marrow-recipient mice treated with an
anti-TNF-a antibody (67).
Transgenic mice overexpressing TNF-a
on a lung-specific promoterdevelop mild pul-
monary fibrosis in a pattern resembling IPF
(68). These mice demonstrate enhanced IL-1
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expression only during an early time point
when lymphocyte proliferation is ongoing.
Interestingly, in contrast to the model tran-
siently overexpressing TNF-a in the lung
using an adenoviral vector (43), TGF-31 pro-
tein expression was decreased in this TNF-a
transgenic mouse. Finally, mice deficient in
TNF-a demonstrate resistance to bleomycin-
induced lymphoid infiltration and increases
in lung collagen content as a measure of
fibrosis (69), which is complementary to the
data described above when employing double
TNF-a receptor knockout mice. All these
transgenic, knockout, and mutant models
support the general and fundamental concept
that TNF-a is necessary for the development
ofpulmonaryfibrosis.
The essentially universal finding of
TNF-a expression in these models ofpul-
monary fibrosis strongly suggests that TNF-a
is required for fibrosis to occur. Yet there is at
least one exception, as in a model ofmurine
pulmonary fibrosis induced by an adenoviral
vector expressing granulocyte macrophage
colony-stimulating factor, where apparently
there is no upregulation ofTNF-a (70).
Thus, it is clear that TNF-a overexpression
leads to pulmonary fibrosis, including those
fibroses caused by inorganic dusts, but
whether TNF-a is required for the multiple
causes ofpulmonary fibrosis remains in ques-
tion. Other questions concerning TNF-a in
the pathogenesis oflung fibrosis remain unan-
swered. For example: What is the duration of
TNF-a overexpression that leads to fibro-
genesis? Wlll continued expression ofTNF-a
lead to further fibrosis or will the col-
lagenolytic effects ofTNF-a in the later stages
be protective for the lung? Some investigators
have proposed that TNF-ax inhibits fibroblast
proliferation during a rapid early phase of
fibroproliferation following an insult, but
TNF-a may stimulate cell proliferation dur-
ing a later repair phase (71). Answers to these
challenging questions will require novel
approaches usinganimal models.
The relationships between animal models
ofTNF-a-induced pulmonary fibrosis and
the diverse patterns ofhuman lungdisease are
not clear, but it is known that specimens of
fibrotic human lung from diverse patterns,
such as bronchiolitis obliterans with organiz-
ing pneumonia (BOOP), the granulomatous
lesions ofsarcoidosis, and the usual interstitial
pneumonitis pattern of IPF, demonstrate
upregulation ofTNF-az expression (72). In
situ hybridization and immunohistochemical
staining have identified mononuclear inflam-
matory cells and type II epithelial cells as
primary sources ofTNF-a within the lung
(20,73). Although some investigators have
reported that TNF-a mRNA levels were not
elevated in alveolar macrophages obtained
from subjects with BOOP or IPF as in
normal subjects (74) and that TNF-a levels
were not elevated in the lung homogenates of
subjects with IPF compared with lung
homogenates ofcontrols (75), others found
increased TNF-a mRNA in macrophages
derived from the lungs ofpatients with IPF
or asbestosis (73,76). Immunohistochemical
staining detected increased TNF-a immuno-
reactivity in hyperplastic alveolar type II cells
in humans with IPF compared with those
with normal lungs (77). In another occupa-
tional cause oflung fibrosis, TNF-a mRNA
expression is increased in human blood
monocytes exposed to beryllium, an inor-
ganic dust that causes a granulomatous
pattern oflungfibrosis (78).
In agreement with the hypothesis that
TNF-a is important in lung fibrogenesis,
drugswith antifibroticproperties, such as pen-
toxyphylline and pirfenidone, which have
been employed in animal models ofpul-
monary fibrosis, demonstrate anti-TNF-a
effects (79,80). Presently, investigators are
studying the effects ofinhibiting TNF-a
expression in granulomatous lung disease (sar-
coidosis) and IPF (81) in humans using pen-
toxyphylline. Pirfenidone appeared to arrest
the progression offibrosis in subjects with IPF
who were deteriorating despite treatment with
corticosteroids and other immunosupressant
drugs (16). Inasmuch as animal models have
confirmed that blocking TNF-a results in
increased susceptibility to respiratory
pathogens (82,83), we should consider that
most animal studies are conducted in
pathogen-free environments and investigators
must exercise caution ifsignificant and pro-
longed inhibition ofTNF-a is used in the
treatmentofchronichuman fibrotic disorders.
Therefore, understanding the roles ofindivid-
ual TNF-a receptors and the TNF-a signal
transduction pathways remain important areas
ofresearch in lungbiology.
Platelet-Derived Growth Factor
An increase in mesenchymal cell number is a
consistent feature offibroticlunglesions (84).
Mesenchymal cells ofthe lung include fibrob-
lasts, smooth muscle cells, and myofibrob-
lasts. Myofibroblasts are the predominant
mesenchymal cell phenotype present in
fibrotic lung lesions ofvarious etiologies
including bleomycin, oxygen toxicity,
asbestos, hypersensitivity pneumonitis,
BOOP, systemic scleroderma, sarcoidosis,
and IPF (85,86). In addition to the mes-
enchymal cell proliferation in fibrotic lesions,
there is also connective tissue deposition.
Lung mesenchymal cells playa major role not
only in synthesis but also in maintenance of
connective tissue through elaboration of
appropriate enzymes (87).
It has become clear that there are multiple
growth factors and cytokines that have the
potential to be contributors to the fibrogenic
process (18,36). In this review, we focus on
PDGF. Among a number ofmesenchymal
cell mitogens, PDGF is the mostpotentand is
a chemoattractant for these cells as well. In
part, we have chosen to investigate the role of
PDGF rather than that ofthe many other
growth factors potentially active in fibroprolif-
erative disease because it has been shown that
other molecules such as IL-1[B, TGF-PI, and
thrombin exert part oftheir mitogenic effects
on mesenchymal cells in vitro indirectly
through PDGF and its receptors (88-90).
PDGF was first isolated from the alpha
granules ofblood platelets (91). Now it is
known that PDGF is secreted by macro-
phages, endothelial cells, smooth muscle cells,
fibroblasts, glial cells, epithelial cells, and
some cancer cells (92). PDGF is a 29- to 38-
kDa glycoprotein dimer composed ofA
and/or B chains linked by disulfide bonds.
The PDGF-A and -B chains share 60%
homology and are located on human chro-
mosomes 7 and 22, respectively. The active
form may exist as an AA or BB homodimer
or as an AB heterodimer. PDGF monomers
are inactive (92. PDGF is a potent mitogen
and chemoattractant for mesenchymal cells
and also promotes production ofglycos-
aminoglycans by mesenchymal cells. The
introduction ofPDGF to mesenchymal cell
cultures is followed by the formation of
polyribosomes and an increased rate of
mRNA translation in the mesenchymal cells,
with subsequent cell proliferation (93).
PDGF acts as a competence factorand stimu-
lates cells to progress from the G1 postmitotic
phase to the Gl pre-DNA synthetic phase of
the cell cycle (91).
PDGF ligands, in dimeric form, bind to
receptor dimers composed ofalpha and beta
subunits (94,95). PDGF receptor (PDGFR)
activation requires dimerization (96).
PDGFR-ax has a high affinity for A and B
chain PDGF, whereas PDGFR-f has a high
affinity only for the PDGF-B chain. The
PDGF chains, covalently bound in an
antiparallel orientation (97), bind to the
receptor subunits and are subsequently
rapidly internalized and degraded with a tl/2
of20 min and 60-90 min, respectively (98).
Binding ofthe PDGF dimers to the receptor
subunits results in transphosphorylation and
subsequent activation ofsignal transduction
pathways, and eventuates in cell proliferation
and chemotaxis (95).
Lung fibroblasts express receptors for a
number ofmitogens including IL-1, throm-
bin, TGF-P, TNF-a, and fibroblast growth
factor (bFGF) (18). Sources forthesecytokines
in the lungs are macrophages and other
inflammatory cells, epithelial and mesenchy-
mal cells, and matrix deposits in the case of
bFGF (18,92). A body ofdata suggests that
Environmental Health Perspectives * Vol 108, Supplement 4 * August 2000 754INTERSTITIAL FIBROSIS AND GROWTH FACTORS
several ofthese molecules (e.g., IL-1P (88,995,
TGF4i1 (89,100,101), thrombin (90,102),
TNF-a (42,103) and bFGF (104), which act
as mitogens for mesenchymal cells, exert all or
part of their growth-promoting activity
through induction ofPDGF-dependent path-
ways. The PDGF-dependent proliferative
activityofthese other mitogens occurs through
upregulation of the PDGF-A chain and
the PDGFR-a.
It is important to understand that the
activity ofPDGF also may be modulated by
other peptides. For example, a2-macroglobu-
lin is a large and abundant serum antiprotease
that serves as a binding protein for all three
PDGF isoforms (105). We have shown that
the binding ofPDGF to a2-macroglobulin is
80% reversible in 1 M acetic acid and thus is
noncovalently bound (105). We know that
a2-macroglobulin is produced by macro-
phages and fibroblasts in the lung, but
presently the biologic effects of(X2-macro-
globulin on the mitogenic activity ofPDGF
are not well understood. a2-Macroglobulin
could enhance the activity ofPDGF by pro-
tecting it from proteolytic degradation or
could limit its availability via clearance of
PDGF bound to a2-macroglobulin because
a2-macroglobulin is internalized after bind-
ingto its receptor (2-(.
A series ofstudies in this field has demon-
strated that PDGF is produced by these mes-
enchymal cell populations (21,106-109).
Accordingly, there are a few reports suggest-
ing that there may be a PDGF-dependent
autocrine proliferative mechanism in lung
fibroblasts. Chen et al. (110) showed that
fibroblasts isolated from the lungs ofhumans
(who have died ofacute lung injury) prolifer-
ate in the absence ofexogenous growth fac-
tors in serum-free medium, whereas those
from the lungs ofcontrols do not. Bishop
et al. (111) have shown that rat lung fibrob-
lasts and a human fetal lung fibroblast cell
line secrete a mesenchymal cell growth factor
and proliferate when stretched on a special-
ized culture membrane. The mitogenic activ-
ity in the medium ofthe stretched cells was
partially blocked by an anti-PDGF antibody.
Directly relevant to our interest in fibrogenic
lung disease caused by environmental agents,
we have shown that treatment offibroblasts
with asbestos fibers results in expression of
PDGF-A chain and upregulation of
PDGFR-a expression, with resultant fibro-
proliferation (21,22). Because PDGF-AA
binds only to the PDGFRa, we have pro-
posed that this concomitant upregulation of
ligand and receptor is a mechanism through
which interstitial asbestos fibers could contin-
uously induce proliferation ofmesenchymal
cells in an autocrine/paracrine pathway.
We now review the data that support the
hypothesis that PDGF is involved in the mes-
enchymal cell proliferation that is the key to
pulmonary fibrosis (Table 1). There is con-
siderable evidence that PDGF plays a role in
the development ofpulmonary fibrosis ofvar-
ious etiologies in animals and humans,
including the recent findings that PDGF and
its receptors are upregulated at the sites of
fibrotic lung lesions in both human pul-
monary fibrosis and in animal models of
the disease.
It is obvious that PDGF is not the only
growth factor contributing to the pathogene-
sis oflung fibrosis; however, the in vitro and
in vivo data strongly suggest that PDGF has
the potential to be a key factor in mediating
mesenchymal cell proliferation in fibro-
proliferative lung disease. For example,
Table 1. Potential of role of PDGF in IPlF
Significant findings
Idiopathic pulmonary fibrosis
Autoimmune-associated pulmonary fibrosis
Acute lung injury
Histiocytosis X
Bronchiolitis obliterans
IPF/Gray platelet
lung tumor associated
Hermansky-Pudlak syndrome
Asbestos
Hyperoxia
Residual oil fly ash particles
Inflammation
Asbestos-exposed
Human lung disease and isolated cells
Alveolar macrophages (AMs) from patients with IPF secrete more PDGFthan AM from subjects without IPF(112).
PDGF-B chain mRNAand protein are localized inthealveolarepithelium, mesothelial cells, and interstitial macrophages (113).
Greater PDGF ligand positive immunostaining is detected in the macrophages of IPF patients versus controls (114).
AM from patients with IPF have a 10-fold increase in PDGF-A and -B chain mRNAcompared to AMs from subjects with
normal lungs, with the B chain 10-fold more abundant than the A chain (115).
In early-stage IPF, PDGF was located within macrophages, fibroblasts, alveolar type 11 cells, and vascular endothelial cells,
whereas PDGF was onlyfound within macrophages in late-stage IPF(116).
An increase in PDGF-B chain mRNA was found in lavaged cells from lungs of patients with autoimmune disease and
pulmonaryfibrosis (117).
PDGF-AA and -BB, as measured by ELISA and Western blotting, is increased in the lavage fluid of patients with
scleroderma compared with that of control subjects (118).
PDGFactivity is present in lung lavage fluid from patients dying with acute lung injury(119).
There is an increase in PDGF-B chain mRNA in bronchoalveolar lavage cells from subjects with histiocytosis X (120).
An increase in the PDGF-B chain is detected in lavage fluid post-transplant prior to the development of bronchiolitis (121).
PDGF-A chain mRNA is detected in inflammatory cells surrounding fibrotic airway lesions(122).
Abnormal megakaryocytes localized in the pulmonary capillaries secrete PDGF(123).
PDGF-B chain and -1 receptor mRNA are found in primary lung tumors exhibiting desmoplasia (124).
PDGF-B chain is detected in lung macrophages (125).
In vitrohuman lung fibroblast asbestos-induced proliferation is blocked by an antisense oligomer to PDGF-A chain (128).
Rodent models of lung fibrosis
PDGF-B chain mRNA is increased in whole lung tissue prior to DNA synthesis and tissue repair(127).
PDGF-A chain mRNA is increased in whole lung tissue following cell proliferation. Also, PDGF-A chain mRNA is induced by
10% fetal bovine serum in isolated rat lung fibroblasts (128).
PDGFR-ca is upregulated in the lung in vivofollowing exposure of rats to residual oil fly ash (129).
PDGFR-a expression is increased in rat lung through IL-1 (130).
Rat AM secrete more PDGF(all three isoforms( following exposure to asbestos in vitro( 134).
Exposure of mineral dust to tracheal explants results in increased expression of PDGF-A and -B chain gene expression (131).
Increased production of PDGF by rat interstitial macrophages following stimulation with asbestos fibers(132).
Rat lung myofibroblasts upregulate PDGFR-a mRNA and cell surface receptor expression following exposure to
asbestos in vitro(22).
Rat lung myofibroblasts express PDGF-A chain mRNA and secrete PDGF-AA in response to asbestos in vitro(21).
Both PDGF-Aand -Bchain mRNAand peptide are upregulated atthe sites ofdeveloping asbestos-induced fibrotic lesions( 19).
PDGFR-a, but notPDGFR-P, mRNA, and peptide are upregulated at the site of asbestos-induced fibrotic lesions (23).
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significant asbestos exposure results in IPF
in humans and rodents, with pathologic and
physiologic features that are observed in a
wide variety of chronic ILDs (133).
Morphometric studies have shown that
asbestos exposure results in an increase in
lung fibroblast numbers and volume at the
alveolar duct bifurcations, where the vast
majority ofasbestos fibers deposit initially
(61). We and others have reported that lung
macrophages release biologically active
PDGF when stimulated with asbestos fibers
(134). Furthermore, asbestos fibers induce
proliferation ofrat lung fibroblasts in serum-
free media through a PDGF-dependent
pathway that involves the PDGF-AA iso-
form and upregulation of the PDGF-a
receptor (21,22). Our in vivo observations
using a murine model ofaerosolized asbestos
exposure demonstrate upregulation of both
PDGF-A and -B chains, predominantly in
macrophages and epithelial cells, at the
alveolar duct bifurcations (19) (Figure 1).
We have also described upregulation of the
PDGF-a, but not the PDGF-,, receptor
within interstitial cells at alveolar duct bifur-
cations after asbestos exposure (23).
Upregulation of the PDGF ligands and the
PDGF-at receptor occurs in concert within
hours following asbestos exposure, and this
early event precedes the observed asbestos-
induced fibrogenesis that can be measured
through subsequent days. Thus, PDGF is
present at the appropriate place and time
during asbestos-induced fibrogenesis and
could be mediating fibroproliferation.
In further support ofa role for PDGF in
lung fibrogenesis, investigators have estab-
lished that overexpression ofPDGF within
the lung will result in development ofpul-
monary fibrosis. Overexpression ofPDGF-B
chain specifically in murine lung under con-
trol of the surfactant protein-C promotor
results in the development ofenlarged air-
spaces and thickened septal walls (135). In
addition, administration ofan expression vec-
torencoding PDGF-B chain into thelungs of
rats results in the development ofpulmonary
fibrosis, and administration ofa vector with
a truncated PDGF-,B receptor that will
Figure 1. (A) The alveolar duct (AD) bifurcations (arrow) in asbestos-exposed rats and mice exhibit strong expression
of several growth factors. Here in situ hybridization for PDGF-A shows clear upregulation in macrophages (arrow-
head), the bifurcations, and bronchiolar epithelium (double arrows) [see Liu et al. (19 for details]. (B) Sense control
for PDGF-A blocks all hybridization. (C) Immunohistochemistry for PDGF-A reveals a staining pattern identical to that
seen by insituhybridization with macrophages (arrowheads) and the duct bifurcations clearly stained. (D) A close-up
of a duct bifurcation reveals a fibroproliferative lesion [see Chang et al. (61) for details] clearly stained for PDGF-A.
The macrophages (arrowhead), alveolar epithelium (arrow) and some interstitial cells exhibit strong staining for
PDGF-A. Illustration courtesy of Dr. Jing-Yao Liu (Department of Pathology, Tulane University School of Medicine,
New Orleans, Louisana).
bind PDGF-B chain-containing isoforms,
markedly alleviated bleomycin-induced
histopathologic changes in murine lung
(136). Furthermore, transient increases in cel-
lularity and collagen deposition occur along
with bromodeoxyurine incorporation within
perivascular and peribronchial fibroblasts fol-
lowing intratracheal delivery ofrecombinant
PDGF-BB (137). In concert, these data pro-
vide convincing evidence that PDGF is capa-
ble ofmediating lung fibroproliferation. On
the other hand, although PDGF is present in
fibrotic lesions and is a potent mesenchymal
cell mitogen and chemoattractant, it remains
to be proven whether this factor is necessary
for human lung fibrogenesis to develop.
Finally, certain compounds that inhibit
the activity ofPDGF block the development
of lung fibrosis. The PDGF signal trans-
duction pathway involves tyrosine kinases
(138,139). Recently, several tyrosine kinase
inhibitors have been developed, some of
which demonstrate selective inhibition of
PDGF receptor tyrosine phosphorylation
(138,139). In a rat tracheal transplant model
ofbronchiolitis obliterans, CGP 53716, a
PDGF receptor-selective tyrosine kinase
inhibitor, blocks the formation ofintralumi-
nal fibroproliferation (140). A significant step
toward demonstrating the critical role played
by PDGF in the pathogenesis oflung fibrosis
was recently published (1391, showing that a
tyrosine kinase inhibitor ofthe tyrphostine
class (that blocks PDGF signal transduction)
blocks mesenchymal cell proliferation and
hydroxyproline accumulation, as a measure of
collagen accumulation, in a rat model of
vanadium pentoxide-induced lung fibrosis.
Further supportive evidence for the role of
PDGF in the development oflung fibrosis is
provided by investigation into the mechanism
ofthe inhibition ofbleomycin-induced pul-
monary fibrosis in hamsters by the antifi-
brotic drug pirfenidone (141). Pirfenidone
did not alter PDGF mRNA expression but
did significantly reduce the synthesis of
PDGF peptide in the lavage fluid of
bleomycin-treated hamsters.
Clearly, it is possible that agents such as
pirfenidone or the tyrosine kinase inhibitors
discussed above may also diminish fibrogenesis
via hitherto unknown effects on other media-
tors offibrosis. Therefore, novel approaches
such as the generation and evaluation of
PDGF transgenic and knockout mice must
be developed to define the role of PDGF in
lung fibrogenesis. As indicated above, mice
that overexpress PDGF-BB using the lung-
specific surfactant protein-C promotor
demonstrate both thickened alveolar septae
and emphysema (135). PDGF knockout
mice have also been generated for each ofthe
PDGF ligand chains and receptors. Mice that
lack the PDGF-A chain are generally not
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viable, and those that are develop pulmonary
emphysema apparently because ofa failure of
alveogenesis along with the lack of lung
myofibroblast development (142,143). This
finding suggests that the PDGF-A chain is
involved in the generation ofthe proliferative
mesenchymal cell phenotype observed in pul-
monary fibrosis. Mice lacking the PDGF-B
chain are also not viable and develop bleeding
because ofpericyte loss and microaneurism
formation (143) along with the absence of
renal glomeruli (144). Investigators recently
have overcome the issues of mortality in
PIJGF knockout mice through generation of
chimeras to substantiate a role for the
PDGF-P receptor in a murine skin wound
model (145). The study of PDGF receptor
knockout chimeras and other such novel
approaches in models oflung fibrogenesis
should be equallyinformative.
TransfonmingGrowth FactorBeta
TGF-1 encompasses a family of closely
related peptides that bind to the same recep-
tors and have nonidentical but similar bio-
logic activities (146). Whereas TGF-.2 and
TGF-,B3 are expressed constitutively in the
lung with little ifany alteration in expression
in response to fibrogenic stimuli, TGF-P1
expression is often upregulated in the lung at
sites offibrogenesis (117,147). Hence, most
published literature on TGF-f1 and this
review focus on this isoform. TGF-P1 is a
25-kDa peptide dimer secreted byseveral pul-
monary cell types, including macrophages,
platelets, epithelial cells, endothelial cells, and
fibroblasts (146). TGF-131 is secreted as a
latent peptide that is cleaved by proteases,
acid hydrolysis, or reactive oxygen species
into an active peptide that is recognized by
several distinct cell surface receptors that are
present on most cell types (146). Two recent
findings may provide exciting future avenues
for regulation ofTGF-11 activity and there-
fore, lung fibrosis. Thrombospondin was
found to be a major activator ofTGF-,B1 by
binding to and inducing a conformational
change in the latency-associated peptide of
TGF-P (148); and the integrin av16, which is
upregulated on epithelial cells in response to
lung inflammation, induces spatial activation
ofTGF-,B1 (149).
TGF-3 type I and type II receptors
facilitate signaling of each other but favor
different biologic activities such as extracellu-
lar matrix accumulation for the type I recep-
tor and modulation of cell growth for the
type II receptor (150). Relatively little was
known until recently regarding the expres-
sion of the TGF-P receptors during lung
fibrogenesis. Northern and Western blot
analyses for TGF-~ receptor types I and II
expression in a rat model of hyperoxia-
induced lung injury and repair demonstrate
similar distribution for the two receptors but
distinct patterns of upregulation during
stages of injury and repair (151). In vitro
experiments in mesenchymal and endothelial
cells have demonstrated that heteromeric
type I-type II receptor complexes are
required for the mitogenic activity ofTGF-P
(152). Expression of a truncated type II
TGF-,B receptor, which acts as a dominant
negative mutant in cultured smooth muscle
cells, results in suppression offibronectin and
type I collagen production (153) and has
been helpful in establishing the role ofTGF-
1 in regulating the synthesis ofthese matrix
elements. 3-Glycan, the TGF-P type III
receptor, enhances the binding ofTGF-P to
its type II receptor and appears to be essential
forTGF-P-mediated negative regulation of
lung organogenesis (154). A TGF-, type V
receptor has recently been described and can
form heterocomplexes with the type I recep-
tor but may also mediate growth inhibition
in the absence ofTGF-1 type I and type II
receptors (19). It would be of interest to
know whether specific biologic activities of
TGF-f, described below, are mediated by
distinct TGF-3 receptor profiles expressed by
cells involved in the pathogenesis of
pulmonary fibrosis.
TGF-P can bind to matrix elements such
as decorin (155) and to the macromolecular
anti-protease a2-macroglobulin (156). These
binding peptides are likely to modulate the
activity ofTGF-,. For example, old fibrotic
tissue associated with adenocarcinomas stains
intensely for decorin but weakly for TGF-f1,
suggesting that decorin plays a role as a nega-
tive feedback regulator in the expression of
TGF-3l (155). Consistent with this hypothe-
sis, repetitive intratracheal administration of
decorin attenuates lungfibrosis in a bleomycin
model oflungfibrosis in hamsters (157).
TGF-PI has numerous biologic activities
including immunomodulatory (158), both
pro- and antimitogenic (159,160), and
profibrotic through increases in extracellular
matrix synthesis and inhibition of matrix
degradation (161). TGF-W_ inhibits prolif-
eration of epithelial cells and thus could
potentially extend the fibroproliferative
phase following lung injury, since reepithe-
lialization is purported to limit the forma-
tion of granulation tissue (162). TGF-,1
has a bimodal response on fibroblast prolif-
eration, which occurs through a PDGF-
dependent pathway. Low doses ofTGF-,I
upregulate PDGF-A chain expression, but
higher doses ofTGF-31 can decrease the
expression of PDGF-ax receptor and thus
negate its own effects on upregulation ofthe
PDGF ligand (89). More recent experiments
using embryonic cells lacking the PDGF-Ca
receptor suggest that about halfthe TGF-,
mitogenic activity for these 3T3-like cells is
mediated via a PDGF-independent pathway
(163). Interestingly, TGF- I blocks PDGF-
dependent proliferation ofprimary rat lung
fibroblasts in vitro (164).
The most notable activity ofTGF-P1 is
its positive effects on extracellular matrix
accumulation. TGF-31 has been shown to
influence collagen accumulation at many of
the key stages in collagen metabolism and
degradation, beginning with induction of
procollagen gene transcription (161,165). A
transgenic mouse containing a rat type 1
alpha-1 collagen promoter fused to the chlo-
ramphenicol acetyltransferase (CAT) reporter
gene has been studied in dermal wound and
bleomycin lung injury models, and revealed
that subcutaneous injection of TGF-W1
increases the CAT transgene expression but
only in a subpopulation ofdermal fibroblasts,
even though alpha-1 collagen was expressed
throughout the dermis (166). Furthermore,
CAT expression was increased 6- to 8-fold
2 weeks postbleomycin exposure, and like the
observations with dermal injection of
TGF-,B1, there was a subpopulation ofcells
around the airways with prominent collagen
mRNA expression but little CAT reporter
gene expression. These findings indicate that
there are distinct groups ofmesenchymal cells
within the dermis and lung capable ofupreg-
ulating their collagen expression following
stimulation with TGF- 1; however, other
mesenchymal cells may require additional
elements forcollagen gene expression.
Collagen synthesis and degradation is an
ongoing process in the lung, and TGF-,B1 has
been shown to reduce the proportion ofpro-
collagen that is degraded within lung fibrob-
lasts prior to secretion (167). Furthermore,
TGF-,1 is capable oflimiting mature extra-
cellular collagen degradation through altering
the balance between collagenases and their
inhibitors (161). TGF-,1I may even induce a
negative feedback pathway that limits its own
enhancement ofprocollagen production by
inducing prostaglandin E2 (161). Although
TGF-3l is generally viewed as a profibrotic
cytokine, investigators have entertained the
hypothesis that TGF-, may be important in
downregulating the T-helper (Th)1 lympho-
cyte response in certain fibrotic lung diseases
such as sarcoidosis, through inhibition ofthe
production ofcytokines (IL-2 and interferon
gamma, for example) involved in propagation
ofgranulomatous inflammation (168). Thus,
TGF-P may limit lung injury by diminishing
inflammation and blocking fibroblast prolif-
eration, but it may also promote lung fibrosis
though stimulation ofmatrix accumulation.
Experiments using human lung fibroblast
isolates in vitro demonstrate that TGF-i1
and -43 induce similar increases in the
percentage of secreted collagens into the
culture supernatants along with increases of
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collagen deposited into the matrix (169). In
addition, both of these TGF-f isoforms
decreased the secretion ofMMP-1 (collage-
nase), but not MMP-2 (gelatinase A), and
increased tissue inhibitor ofmetaloproteinase
(TIMP)-1 but not TIMP-2. Importantly,
TGF-f mediates collagen accumulation in
human lung fibroblasts through increased
collagen synthesis and decreased collagen
degradation.
Multiple reports demonstrate increased
expression ofTGF-i1 mRNA and peptide in
fibrotic human lung specimens including
those with asbestosis (170), silicosis (171),
titanium dioxide (131), IPF, eosinophilic
granulomatosis, and sarcoidosis (172).
TGF-, immunohistochemical staining and
mRNA expression are increased in the lungs
ofhumans afflicted with IPF and localize
within inflammatory regions and at sites of
extracellular matrix expression, thereby impli-
catingTGF-P in the pathobiology occurring
at these fibroproliferative sites (173). IPF lung
specimens reveal TGF-,P within alveolar
type II cells, which coincides with, and may
be responsible for, the increase in alpha
smooth muscle actin expression within adja-
cent lung mesenchymal cells (77). TGF-11
peptide levels are elevated in lung lavage fluid
from patients with IPF as well as those with
sarcoidosis and abnormal lung function
studies compared to healthy subjects and
those with sarcoidosis and normal lung func-
tion (174). Patients with eosinophilic granu-
lomatosis had prominent staining for
TGF-f1 within macrophages and type II
pneumocytes in actively inflamed lesions but
not in advanced fibrotic lesions (175).
Analysis ofTGF-3 isoform expression was
conducted on lung specimens from humans
with UIP, nonspecific interstitial pneumoni-
tis, asbestosis, and hypersensitivity pneu-
monitis and revealed that TGF-P2 and -P3
expression was ubiquitously expressed and
was not increased in fibrotic specimens com-
pared with normal lung specimens, whereas
TGF-P1 expression was increased within lung
macrophages (176). Furthermore, TGF-f 1
levels were also measured in the lung lavage
fluid of48 patients with IPF by enzyme-
linked immunosorbent assay (ELISA), and
the authors noted that patients with the high-
est TGF-1l levels had significantly shorter
survival rates compared with patients who
had intermediate and low TGF-f1 levels
(177). Other investigators reported immuno-
histochemical localization ofTGF-1 1 in
fibrotic lung within epithelioid histiocytes,
type II pneumocytes, bronchiolar epithelial
cells, and alveolar macrophages (174).
Immunohistochemical staining forTGF-P1
in subjects with silicosis demonstrated dense
staining within central hyalinized areas ofthe
silicotic nodules and in scar tissue from areas
with progressive massive fibrosis, whereas the
TGF-,1 staining for subjects with acute sili-
cosis was localized within macrophages and
hyperplastic alveolar epithelium (171). Thus,
TGF-P expression is increased in many cell
types during lung fibrogenesis, but specific
cell types may vary according to the etiology
orstage ofthe fibrotic disease.
TGF-,B1 mRNA expression correlates
spatially and temporally with collagen expres-
sion in lung development and in animal
models oflung fibrosis (178,179). Though
TGF-P1 mRNA is expressed in the lung con-
stitutively, it is upregulated in several animal
models oflung fibrosis including bleomycin
(162) and asbestos-induced lung injury (180).
In normal mouse lung, TGF-f1 and -P3
transcripts are identified within bronchiolar
epithelium, but following bleomycin expo-
sure TGF-,1 expression was enhanced, pre-
dominantly within macrophages but also
within mesenchymal cells, endothelial cells,
and mesothelial cells (147).
In a murine model ofirradiation-induced
lung fibrosis, antibodies to the TGF-1I
latent reactive protein and to the active con-
formation ofTGF-P1 demonstrated staining
only in a sensitive strain compared with a
resistant strain, and localized TGF-,1 pep-
tide expression within fibroblasts at the sites
of fibrotic lesions (181). TGF-P1 peptide
and mRNA expression are increased in rat
lung 3-6 weeks following irradiation coin-
ciding with an influx of inflammatory cells
in BAL and preceding the fibrosis that
appeared 8-10 weeks following irradiation
(137). TGF-fi1 immunohistochemical stain-
ing is increased during a fibrotic phase in a
murine model of pulmonary tuberculosis
and also in a Fas antibody model ofapopto-
sis/fibrosis in mice (182). Overexpression of
granulocyte macrophage colony-stimulating
factor in the lung using an adenoviral vector
induced the formation oflung granulation
tissue, in part by induction of TGF-1I
expression within lung myofibroblasts; it
also caused macrophages lavaged from the
lungs ofthese mice to secrete more TGF-j
into their culture media (70). The overex-
pression ofTGF-,B1 in these animal models
oflung fibrosis correlates with the findings
in human lung previously discussed.
Data demonstrating that inhibition of
TGF-[1 arrests or decreases lung fibrosis have
been published but are limited in number.
Anti-TGF-f31 antibodies reduce fibrosis in an
animal model of bleomycin-induced lung
fibrosis (183,184). Recently, intratracheal
administration ofa soluble TGF-B type II
receptor significantly reduced bleomycin-
induced fibrotic lung histopathogy and
hydroxyproline accumulation in hamsters
(185). Furthermore, taurine and niacine are
believed to decrease bleomycin-induced
fibrosis in hamsters via inhibition ofTGF-P3I
mRNA expression (141). In addition, mea-
sures taken to decrease lung fibrosis appear
also to diminishTGF-P expression. In a com-
parative analysis ofTGF-,1 mRNA and pro-
tein expression in asbestos-sensitive and
-resistant mice, TGF-, 1 expression was lower
in the resistant strain (62). In addition,
TGF- 1 expression is essentially lacking in
the lungs of the asbestos-exposed TNF-a
receptor knockout mice previously described
(20). This is consistent with the concept that
TNF-ax upregulates the expression of
TGF-,1, an important idea to consider in
those systems in which multiple factors are
active simultaneously during disease develop-
ment. In other modes, immunohistochemical
localization ofTGF-,1 in an ovine model of
asbestos-induced lung fibrosis demonstrated
increased staining for TGF-I1 within the
interstitial matrix (186). Investigation into
mediators ofairway wall fibrosis induced by
mineral dusts (asbestos, iron oxide, titanium
dioxide) in rat tracheal explants demonstrates
increases in TGF-1 gene expression, which
is localized to both the epithelium and sub-
epithelial space (130). In a murine model of
asbestosis (187), TGF-[1 activity was found
within myofibroblasts with alpha smooth
muscle actin, but in contrast, immuno-
localization in a rat silicosis model demon-
strated co-localization ofTGF-,B1 and type 1
collagen mRNA expression within cells not
expressing smooth muscle actin. In vitro,
TGF-f1 induces expression ofalpha smooth
muscle actin in lung fibroblasts (188) and
produces a phenotype similar to that ofthe
myofibroblasts encountered in the pathology
specimens derived from fibrotic lung (85).
Furthermore, administration ofneutralizing
TGF-f1 antibodies to rat lung progenitor
fibroblasts in culture resulted in abolition of
TGF-11-induced terminal differentiation to
post-mitotic functional fibrocytes. These cells
were similar in appearance to the mesen-
chymal cell phenotype observed in models of
irradiation-induced fibrosis (189). Thus, lung
fibrosis with varying etiologies may lead to
expansion ofdifferent mesenchymal cell phe-
notypes (190), and TGF-,1 induces alpha
smooth muscle actin expression in some lung
mesenchymal cells. In concert with this cen-
tral observation, it is clear that TGF-jI1 is
overexpressed in smooth muscle actin-
expressing and nonsmooth muscle actin-
expressing lung mesenchymal cells during
lungfibrogenesis.
Delivery ofTGF-031 into the lungs ofrats
usingthehemaagglutinatingvirus ofJapan and
liposome deliverysystem results in lungfibrob-
last proliferation and collagen deposition
(191). In other studies, introduction of
TGF-,11 into the trachea using a recombinant
adenoviral vector causes histopathologic
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changes in rats consistent with pulmonary
fibrosis (192). Overexpression ofTGF-1I
through an adenoviral vector administered to
rats by tracheal instillation leads to severe
parenchymal and airway fibrosis. Two
TGF-p1 constructs were generated for use
with the adenoviral vector, one latent and one
active by nature ofdeletion ofthe fragment
encoding for the latency-associated peptide;
however, only the active construct induced a
fibrotic reaction. The broad spectrum ofTGF-
P activity in lungbiology is apparent from the
fate ofTGF-1 knockout mice. Mice lacking
TGF-,1I die secondary to chronic multifocal
inflammation and also demonstrate inhibition
of lung branching morphogenesis (158),
whereas mice lackingTGF-P3 die shortly after
birthwith abnormallydevelopedlungs (193).
To date, specific anti-TGF-P-directed
therapy has not been forthcoming. Reasons
for this are several. TGF-1 has numerous
biologic effects including profibrogenic, anti-
inflammatory, immunoregulatory, and mod-
ification ofcell adhesion. Ablation of these
TGF-11-mediated activities may be deleteri-
ous. This was found to be the case in TGF-
P11 null mice, which succumb to severe
pulmonary, dermal, and bowel inflammation
within weeks after birth (158). Anti-TGF-
P11 therapy could lead to lung inflammation,
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Figure 2. CTGF and alpha 1 type collagen mRNA
expression are increased in mouse lung 7 days after
administration of an adenoviral vector containing an
active TGF-,B1 construct. C57BL/6 mice were given an
adenovirus with (T) or without (C) the inclusion of an
active TGF-p1 construct via intratracheal injection (109
cful, which resulted in lung fibrosis only in mice that
received the virus with the active TGF-l1 construct. RNA
was isolated from the lungs 7 days after virus adminis-
tration. Administration of the adenovirus with the active
TGF-31 construct resulted in increased expression of
CTGF, and alpha-i type procollagen mRNA expression,
compared to the control adenovirus. 36B4 encodes for a
ribosomal protein and is used as a loading control in this
experiment. Illustration courtesy of Dr. Saku
Warshamana (Department of Pathology, Tulane
University School of Medicine, New Orleans, Louisana).
which would be counterproductive in
fibrotic lung disease, as inflammation is rec-
ognized to be an early and essential compo-
nent offibroproliferative lung disease (29).
Furthermore, since mutant TGF-13 type II
receptor mice demonstrate increased inci-
dences ofbreast and lung cancer, it is impor-
tant to identify the role of the individual
TGF-P receptors in lung fibrogenesis in light
ofthis finding (194).
Therapy directed toward downstream
mediators ofTGF-P activity may be more
prudent, for example, using CTGF or mole-
cules that may modulate the activity ofTGF-
P such as decorin (157) may be clinically
more practical. Decorin is a matrix peptide
that binds TGF-,1I, and has been shown to
reduce but not eliminate histopathologic
changes offibrosis as well as hydroxyproline
accumulation and neutrophilic infiltration in
hamster lungs treated with bleomycin (157).
Relaxin has also been studied in vitro and in
vivo and was found to block TGF-31 effects
on collagen metabolism (195). Relaxin
inhibits induction ofcollagen types I and III
byTGF-,B in human lungfibroblasts by 45%,
and also stimulates the production of
MMP-1. In vivo, relaxin blocked bleomycin-
induced fibrotic histopathology as well as
lung collagen accumulation when assessed by
hydroxyproline content (195).
Culture ofalveolar macrophages derived
from the lungs of bleomycin-treated rats
demonstrates maximally active TGF-,1
secretion 7 days after bleomycin exposure,
coinciding with the expression of plasmin
(176). These results may point to a key
process that regulates TGF- 1 activity and
could potentially be targeted therapeutically
with protease inhibitors. Since TGF-1
requires cleavage ofthe latent peptide to acti-
vate its biologic activity and because plasmin
is thought to be a major enzyme involved in
this proteolytic cleavage, investigators have
studied urokinase-type plasminogen activator
knockout mice in a murine model ofsilica-
induced fibrosis (196). Although silica
induced increases in plasminogen activator
activity in wild-type mice, in contrast to other
studies, urokinase-type plasminogen activator
knockout mice demonstrated increases in
total and active TGF-1I secretion by
explanted lung macrophages, and active
TGF-1 expression was not different from that
ofsilica-treatedwild-type mice.
At presentseveral investigators areexploring
the role ofCTGF in the pathogenesis oflung
fibrosis in view ofstudies demonstrating that
CTGF shares many of the profibrogenic
activities attributed to TGF-,B (197). CTGF
expression is induced by TGF-,, and CTGF
upregulates the synthesis ofprominent matrix
elements such as collagen and fibronectin
(198), 50 it is likely that some of the TGF-~
profibrogenic activities are mediated through
CTGF. Both TGF-P and CTGF expression
are upregulated in the murine bleomycin
model oflung fibrosis (23), and administra-
tion ofan active TGF-31 construct to murine
lung using an adenoviral vector results in
both increased CTGF mRNA expression and
fibrosis (Figure 2).
Attention should now be focused on the
contribution ofthe various TGF-, receptors
to lung fibrogenesis and on defining the key
factors downstream from TGF-1 that mod-
ulate the individual activities ofTGF-1,
including elements in the TGF-P signal
transduction pathway. It would be interest-
ing to evaluate the effect of administration
ofnewly described TGF-,1 peptide antago-
nists at various phases of lung injury and
development (199) to ascertain whether they
block binding ofTGF-P to its receptor iso-
forms equally well. Finally, a study by Awad
et al. (200) has found that a specific
TGF-P1 polymorphism is linked to pre-
transplant fibrotic pathology and lung trans-
plant allograft fibrosis. Their findings
warrant an extended analysis on larger num-
bers of patients with fibrotic lung disease.
The mechanism through which this poly-
morphism predisposes subjects to develop
lung fibrosis remains completely unidentified
at this time.
REFERENCES AND NOTES
1. Coultas DB, Zumault RE, Baick W, Sobonya RE. The epidemiol-
ogy of interestitial lung diseases. Am J Respir Crit Care Med
150:967-972 (1995).
2. Schwarz Ml. Approach to the understanding, diagnosis, man-
agement of interstitial lung disease. In: Interstitial Lung
Disease, 3rd ed (Schwarz Ml, King TE, eds). St. Louis,
MO:Mosby, 1998;3-30.
3. Katzenstein ALA, Askin FB. Surgical Pathology of Non-
Neoplastic Lung Disease. Philadelphia:WB Saunders,
1990;9-57.
4. Streiter RM Keane MP, Standiford TJ, Kunkel SL. Cytokine biol-
ogy and the patrhogenesis of interstsitial lung disease In:
Interstitial Lung Disease, 3rd ed (Schwarz Ml, King TE, eds).
St. Louis, MO:Mosby, 1998;181-206.
5. Carrington CB, Gaensler EA, Coutu RE, Fitzgerald, MX, Gupta,
RG. Natural history and treated course of usual and desquama-
tive interstitial pneumonia. N EngI J Med 298:801-809 (1978).
6. Travis WD, Ferrans V, Crystal, R. Survival in idiopathic pul-
monary fibrosis (IPF): with histologic correlations in lung biop-
sies from 100 patients. Pathol lnt46:775A(1996).
7. Rom WN, ed. Environmental & Occupational Medicine, 3rd ed.
Philadelphia/New York:Lippincott-Raven, 1998.
8. Schwarz Ml. Idiopathic Pulmonary Fibrosis. West J Med
149:199-203 (1988).
9. Hubbard R, Lewis S, Richards K, Johnston I, Britton J.
Occupational exposure to metal or wood dust and aeteiology of
cryptogenic fibrosing alveolitis. Lancet 347:284-289 (1996).
10. Osornio-Vargas A, Hernandez-Rodriguez NA, Yanez-Buruel AG,
Ussler W, Overby LH, Brody AR. Lung cell toxicity experimen-
tally induced by a mixed dust from Mexicali, Baja California,
Mexico. Environ Res 56:31-47 (1991).
11. Baumgartner KB, Samet, J, Stidley, CA, the collaborating cen-
ters. Cigarette smoking: a risk factor for idiopathic pulmonary
fibrosis. Am J RespirCritCare Med 155:242-248(1997).
12. Chan ED, Worthen GS, Augustin A, Lapadat R, Riches DWH.
Inflammation in the pathogenesis of interstitial lung disease. In:
Interstitial Lung Disease, 3rd ed (Schwarz Ml, King TE, eds). St.
Louis, MD:Mosby, 1998:135-164.
13. Watters LC, Schwarz MI, Cherniac RM, Waldron JA, Dunn TL,
Stanford RE, King JE. Idiopathic pulmonary fibrosis: pretreat-
Environmental Health Perspectives * Vol 108, Supplement 4 * August 2000 759LASKY AND BRODY
ment bronchoalvelolar lavage cellular constituants and their
relationships with lung pathology and clinical response to ther-
apy. Am Rev Respir Dis 135:696-704 (1987).
14. Turner-Warwick M, Haslam Pl. The value of serial bronchoalve-
olar lavage in assessing the clinical progress of patients with
cryptogenic fibrosing alveolitis. Am Rev Respir Dis 135:26-34
(1987).
15. O'Donnell DE. Physiology of interstitial lung disease. In:
Interstitial Lung Disease, 3rd ed )Schwarz Ml, King TE, eds). St.
Louis, MO:Mosby, 1998;51-70.
16. Raghu G, Johnson WC, Lockhard D, Mageto Y. Treatment of
idiopathic pulmonary fibrosis with a new antifibrotic agent, pir-
fenidone: results of a prospective, open-label Phase II study.
Am J Respir Crit Care Med 159:1061-1069 (1999).
17. Chambers RC and Laurent GL. Collagens. In: The Lung Scientific
Foundations. 2nd ed. Philadelphia:Lippincott Raven,
1997;709-728.
18. Kelley J. Cytokines of the lung. Am Rev Respir Dis 141:765-788
(1990).
19. Liu J-Y, Morris GF, Lei W-H, Hart CE, LaskyJA, Brody AR. Rapid
activation of PDGF-A and -B expression at sites of lung injury in
asbestos-exposed rats. Am J Respir Cell Mol Biol 17:129
(1997).
20. Liu J-Y, Brass DM, Hoyle GW, Brody AR. TNF-alpha receptor
knockout mice are protected from the fibroproliferative effects
of inhaled asbestos fibers. Am J Pathol 153(6):1839-1847
(1998).
21. Lasky JA, Coin PG, Lindroos PM, Ostrowski LE, Brody AR,
Bonner JC. Chrysotile asbestos stimulates PDGF-AA production
by rat lung fibroblasts in vitro: evidence for an autocrine loop.
Am J Respir Cell Mol Biol 12:162-170 (1995).
22. Bonner JC, Goodell AL, Coin PG, Brody AR. Chrysotile asbestos
upregulates gene expression and production of alpha receptors
for platelet-derived growth factor (PDGF-AA) on rat lung fibrob-
lasts. J Clin Invest92:425-430 (1993).
23. Lasky JA, Liu J-Y, Tonthat B, Friedman M, Brody AR.
Upregulation of the PDGF-alpha-receptor precedes the develop-
ment of asbestos-induced lung fibrosis in rats. Am J Respir Crit
Care Med 157:1652-1657 (1998).
24. Johnson MA, Kwan S, Snell SJC, Nunn AJ, Darbyshire JH,
Turner-Warwick M. Randomized control trial comparing pred-
nisolone alone with cyclophosphamide and low dose pres-
nisolone in combination in cryptogenic fibrosing alveolitis.
Thorax 44:280-288 (1989).
25. Raghu G, Depaso WJ, Cain K Hammar SP, Wetzel CE, Dreis DF,
Hutchison J, Pardee NE, Wintenhauser RH. Azathioprine com-
bined with prednisone in the treatment of idiopathic pulmonary
fibrosis: a prospective double blind placebo-controlled trial. Am
Rev Respir Dis 144:291-296(1991).
26. Douglas WW, Ryu JH, Swensen SJ, Offord KP, Schroeder DR,
Caron GM, DeRemee RA. Colchicine versus prednisone in the
treatment of idiopathic pulmonary fibrosis. A randomized
prospective study. Members of the Lung Study Group. Am J
Respir Crit Care Med 158(1):220-225 (1998).
27. Geismar LS, Hennesey LH, Reiser KM, Last JA. D-Penicilllamine
prevents collagen accumulation in lungs of rats given
bleomycin. Chest89:153S-154S (1996).
28. Moolman JA, Bardin PG, Rossouw DJ, Joubert JR. Cyclosporin
as a treatment for intersitital lung disease of unknown aetiol-
ogy. Thorax 46:592-595 (1991).
29. Wolff G, Crystal RG. Biology of pulmonary fibrosis. In: The Lung:
Scientific Foundations, 2nd ed (Crystal RG, West J, eds).
Philadelphia:Lippincott-Raven, 1997.
30. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B.
An endotoxin-induced serum factor that causes necrosis of
tumors. Proc NatI Acad Sci USA 72(9):3666-3670 (1975).
31. Sporn MB, Roberts AR. Peptide Growth Factors and Their
Receptors. New York:Springer-Verlag, 1991.
32. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL,
Chen WJ, Clay WC, Didsbury JR, Hassler D, et al. Cloning of a
disintegrin metalloproteinase that processes tumour-necrosis
factor-alpha. Nature 385(6618):733-736 (1997).
33. Vandenabeele P, DeClerq W, Beyeart R, Fiers W. Two tumor
necrosis factor receptors: structure and function. Trends Cell
Biol 5:392-399 (1995).
34. Beutler B and VanHuffel C. Unraveling function in the TNF lig-
and and receptor families. Science 265:667-668 (1994).
35. Bazzoni F and Beutler R. The tumor necrosis factor ligand and
receptor families. N EngI J Med 334:1717-1725 (1996).
36. Strieter RM, Keane MP, Standiford TJ, Kunkel SL. Cytokine biol-
ogy and the pathogenesis of Interstitial lung disease. In:
Interstitial Lung Disease, 3rd ed (Schwarz Ml, King TE, eds). St
Louis, MD:Mosby, 1998;181-206.
37. Piguet PF, Vesin C. Treatment by human recombinant soluble
TNF receptor of pulmonary fibrosis induced by bleomycin or sil-
ica in mice. Eur RespirJ 7(3):515-518(1994).
38. Lou J, Donati YR, Juillard P, Giroud C, Vesin C, Mili N, Grau GE.
Platelets play an important role in TNF-induced microvascular
endothelial cell pathology. Am J Pathol 151(5):1397-1405
(1997).
39. Zhang K, Gharaee-Kermani M, McGarry B, Remick D, Phan SH.
TNF-alpha-mediated lung cytokine networking and eosinophil
recruitment in pulmonary fibrosis. J Immunol 158(2):954-959
(1997).
40. Gharaee-Kermani M, McGarry B, Lukacs N, Huffnagle G, Egan
RW, Phan SH. The role of IL-5 in bleomycin-induced pulmonary
fibrosis.J Leukoc Biol 64(5):657-666 (1998).
41. Smith RE, Strieter RM, Phan SH, Lukacs NJ, Kunkel SL. TNF and
IL-6 mediate MIP-lalpha expression in bleomycin-induced lung
injury. J Leukoc Biol 64(4):528-536 (1998).
42. Paulsson Y, Austgulen R, Hofsli E, Heldin CH, Westermark B,
Nissen-Meyer J. Tumor necrosis factor-induced expression of
platelet-derived growth factor A-chain messenger RNA in
fibroblasts. Exp Cell Res 180:490-496 (1989).
43. Sime PJ; Marr RA; Gauldie D; Xing Z; Hewlett BR; Graham FL;
Gauldie J. Transfer of tumor necrosis factor-alpha to rat lung
induces severe pulmonary inflammation and patchy interstitial
fibrogenesis with induction of transforming growth factor-betal
and myofibroblasts. Am J Pathol 153)3):825-832 (1998).
44. Diaz A, Munoz E, Johnston R, Korn JH, Jimenez SA. Regulation
of human lung fibroblast alpha 1(1) procollagen gene expression
by tumor necrosis factor alpha, interleukin-1 beta, and
prostaglandin E2. J Biol Chem 268(14):10364-10371 (1993).
45. Mori K, Hatamochi A, Ueki H, Olsen A, Jimenez SA. The tran-
scription of human alpha 1(1) procollagen gene (COLlA1) is sup-
pressed by tumour necrosis factor-alpha through proximal short
promoter elements: evidence for suppression mechanisms
mediated bytwo nuclear-factor binding sites. Biochem J 319 (Pt
3):81 1-816(1996).
46. Lin J, Liliensiek B, Kanitz M, Schimanski U, Bohrer H, Waldherr
R, Martin E. Kauffmann G. Ziegler R, Nawroth PP. Molecular
cloning of genes differentially regulated byTNF-alpha in bovine
aortic endothelial cells, fibroblasts and smooth muscle cells.
Cardiovasc Res 38)3):802-813 (1998).
47. Elias JA, Freundlich B, Adams S, Rosenbloom J. Regulation of
human lung fibroblast collagen production by recombinant inter-
leukin-1, tumor necrosis factor, and interferon-gamma. Ann N Y
Acad Sci 580:233-244 (1990).
48. Brenner DA, O'Hara M, Angel P, Chojkier M, Karin M. Prolonged
activation ofjun and collagenase genes by tumour necrosis fac-
tor-alpha. Nature 337(6208):661-663 (1989).
49. Nagakawa H, Kitagawa H, Aikawa Y. Tumor necrosis factor
stimulates gelatinase and collagenase production by granula-
tion tissue in culture. Biochem Biophys Res Commun
142:791-797 (1987).
50. King TE. Connective tissue disease. In: Interstitial Lung Disease,
3rd ed (Schwarz Ml, King TE, eds). St Louis, MO:Mosby,
1998;451-506.
51. Phan SH, Kunkel SL. Lung cytokine production in bleomycin-
induced pulmonary fibrosis. Exp Lung Res Jan-Mar;18(1):29-43
(1992).
52. Ortiz LA, LaskyJ, Hamilton RFJr, Holian A, Hoyle GW, Banks W,
Peschon JJ, Brody AR, Lungarella G, Friedman M. Expression of
TNF and the necessity of TNF receptors in bleomycin- induced
lung injury in mice. Exp Lung Res 24(6):721-743 (1998).
53. Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P. Tumor
necrosis factor/cachectin plays a key role in bleomycin-induced
pneumopathy and fibrosis. J Exp Med 170(3):655-663 1989.
54. Piguet PF, Collart MA, Grau GE, Sappino AP, Vassalli P.
Requirement of tumour necrosis factor for development of
silica-induced pulmonary fibrosis. Nature 344(6263):245-247
(1990).
55. Ohtsuka Y, Munakata M, Ukita H, Takahashi T, Satoh A,
Homma Y, Kawakami Y. Increased susceptibility to silicosis and
TNF-alpha production in C57BL/6J mice. Am J Respir Crit Care
Med 2:2144-2149 (1995).
56. Gossart S, Cambon C, Orfila C, Seguelas MH, Lepert JC, Rami J,
Carre P, Pipy B. Reactive oxygen intermediates as regulators of
TNF-alpha production in rat lung inflammation induced by silica.
J Immunol 156(4):1540-1548 (1996).
57. Davis GS, Pfeiffer LM, Hemenway DR. Persistent overexpres-
sion of interleukin-lbeta and tumor necrosis factor-alpha in
murine silicosis. J Environ Pathol Toxicol Oncol 17(2):99-114
(1998).
58. Ortiz LA, Lasky J, Lungarella G, Cavarra E, Martorana P, Banks
WA, Peschon JJ, Schmidts HL, Brody AR, Friedman M.
Upregulation of the p75 but not the p55 TNF-alpha receptor
mRNA after silica and bleomycin exposure and protection from
lung injury in double receptor knockout mice. Am J Respir Cell
Mol Biol 20(4):825-833 (1999).
59. Kienast K, Bay M, Drumm K, Smolarski R, Ferlinz R. Modulation
of TNF-alpha secretions by alveolar macrophages and blood
monocytes after soot-particle or asbestos fibre exposure. Eur J
Med Res 1(9):425-428 (1996).
60. Driscoll KE, Hassenbein DG, Carter JM, Kunkel Sl, Quinlan TR,
Mossman BT. TNF alpha and increased chemokine expression
in rat lung after particle exposure. Toxicol Lett 83:483-489
(1995).
61. Chang L-Y, Overby LH, Brody AR, Crapo JD. Progressive lung
cell reactions and extracellular matrix production after a brief
exposure to asbestos. Am J Pathol 131:156-170 (1988).
62. Brass DM, Hoyle GW, Poovey HG, Liu JY, Brody AR. Reduced
tumor necrosis factor-alpha and transforming growth factor-
betal expression in the lungs of inbred mice thatfail to develop
fibroproliferative lesions consequent to asbestos exposure. Am
J Pathol 154(3):853-862 (1999).
63. UhI EW, Moldawer LL, Busse WW, Jack TJ, Castleman WL.
Increased tumor necrosis factor-alpha (TNF-alpha) gene expres-
sion in parainfluenza type 1 (Sendai) virus-induced bronchiolar
fibrosis. Am J Pathol 152(2):513-522 (1998).
64. Reinhart PG, Gairola CG. Amiodarone-induced pulmonary toxic-
ity in Fischer rats: release of tumor necrosis factor alpha and
transforming growth factor beta by pulmonary alveolar
macrophages. J Toxicol Environ Health 52(4):353-365 (1997).
65. Johnston CJ, Piedboeuf B, Rubin P, Williams JP, Baggs R,
Finkelstein JN. Early and persistent alterations in the expres-
sion of interleukin-1 alpha, interleukin-1 beta and tumor necro-
sis factor alpha mRNA levels in fibrosis-resistant and sensitive
mice after thoracic irradiation. Radiat Res 145(6):762-767
(1996).
66. Miyazaki Y, Araki K, Vesin C, Garcia I, Kapanci Y, Whitsett JA,
Piguet PF, Vassalli P. Expression of a tumor necrosis factor-
alpha transgene in murine lung causes lymphocytic and fibros-
ing alveolitis. A mouse model of progressive pulmonary fibrosis.
J Clin Invest 96(1(:250-259 (1995).
67. Thrall RS, Vogel SN, Evans R, Shultz [D. Role of tumor necrosis
factor-alpha in the spontaneous development of pulmonary
fibrosis in viable motheaten mutant mice. Am J Pathol
(5):1303-1310 (1997).
68. Sueoka N, Sueoka E, Miyazaki Y, Okabe S, Kurosumi M,
Takayama S, Fujiki H. Molecular pathogenesis of interstitial
pneumonitis with TNF-alpha transgenic mice. Cytokine
10(2):124-131 (1998).
69. Piguet PF, Kaufman S, Barazzone C, Muller M, Ryffel B, Eugster
HP. Resistance of TNF/LT alpha double deficient mice to
bleomycin-induced fibrosis. lnt J Exp Pathol 78(1):43-48 (1997).
70. Xing Z, Tremblay GM, Sime PJ, Gauldie J. Overexpression of
granulocyte-macrophage colony-stimulating factor induces pul-
monary granulation tissue formation and fibrosis by induction of
transforming growth factor-beta 1 and myofibroblast accumula-
tion. Am J Pathol 150(1(:59-66 (1997).
71. Dubaybo BA. Role of tumor necrosis factor-alpha in regulating
fibrotic lung repair. Res Commun Mol Pathol Pharmacol.
Ju1;101(1):69-83 (1998).
72. Ziegenhagen MW, Schrum S, Zissel G, Zipfel PF, Schlaak M,
Muller-Quernheim J. Increased expression of proinflammatory
chemokines in bronchoalveolar lavage cells of patients with
progressing idiopathic pulmonary fibrosis and sarcoidosis. J
Investig Med46(5):223-231 (1998).
73. Piguet PF, Ribaux C, Karpuz V, Grau GE, Kapanci Y. Expression
and localization of tumor necrosis factor-alpha and its mRNA in
idiopathic pulmonary fibrosis. Am J Pathol 143(3):651-655
(1993).
74. Martinez JA, King TE Jr, Brown K, Jennings CA, Borish L,
Mortenson RL, Khan TZ, Bost TW, Riches DW. Increased
expression of the interleukin-10 gene by alveolar macrophages
in interstitial lung disease. Am J Physiol 273(3, Pt 1):L676-683.
75. Smith DR, Kunkel SL, Standiford TJ, Rolfe MW, Lynch JP Ill.
Arenberg DA, Wilke CA, Burdick MD, Martinez FJ, Hampton JN,
et al. Increased interleukin-1 receptor antagonist in idiopathic
pulmonary fibrosis. A compartmental analysis. Am J Respir Crit
Care MedJ151(6):1965-1973 (1995).
76. Zhang Y, Lee TC, Guillemin B, Yu MC, Rom WN. Enhanced IL-1
beta and tumor necrosis factor-alpha release and messenger
RNA expression in macrophages from idiopathic pulmonary
fibrosis or after asbestos exposure. J Immunol 50(9):4188-196
(1993).
77. Kapanci Y, Desmouliere A, Pache JC, Redard M, Gabbiani G.
Cytoskeletal protein modulation in pulmonary alveolar myofi-
broblasts during idiopathic pulmonary fibrosis. Possible role of
transforming growth factor beta and tumor necrosis factor
alpha. Am J Respir Crit Care Med 152:22163-22169 (1995).
760 Environmental Health Perspectives * Vol 108, Supplement 4 * August 2000INTERSTITIAL FIBROSIS AND GROWTH FACTORS
78. Galbraith GM, Pandey JP, Schmidt MG, Arnaud P, Goust JM.
Tumor necrosis factor alpha gene expression in human mono-
cytic THP-1 cells exposed to beryllium. Arch Environ Health
51(1):29-33 (1996).
79. Cain WC, Stuart RW, Lefkowitz DL, Starnes JD, Margolin S,
Lefkowitz SS. Inhibition of tumor necrosis factor and subse-
quent endotoxin shock by pirfenidone. lnt J Immunopharmacol
20(12):685-695 (1998).
80. lyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on
procollagen gene expression at the transcriptional level in
bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther
289(1):211-218(1999).
81. Entzian P, Schlaak M, Seitzer U, Bufe A, Acil Y, Zabel P.
Antiinflammatory and antifibrotic properties of colchicine: impli-
cations for idiopathic pulmonary fibrosis. Lung 175(1):41-51
(1997).
82. Kolls, JK, Lei D, Nelson S, Summer WR, Greenberg S, Beutler B.
Adenovirus-mediated blockade of tumor necrosis factor in mice
protects against endotoxic shock yet impairs pulmonary host
defense. J Infect Dis 171(3(:570-575 (1995).
83. Kolls JK, Lei D, Vazquez C, Odom G, Summer WR, Nelson S,
Shellito J. Exacerbation of murine Pneumocystis carinii infec-
tion by adenoviral-mediated gene transfer of a TNF inhibitor.
Am J Respir Cell Mol Biol 16(2):1 12-118(1997).
84. Crouch E. Pathobiology of pulmonary fibrosis. Am J Physiol
259:159-184 (1990).
85. Adler KB, Low RW, Leslie KO, Mitchell J, Evans JN. Contractile
cells in normal and fibrotic lung. Lab Invest 60:473-485 (1989).
86. Vyalov SL, Gabbianani G, Kapanci Y. Rat alveolar myofibrob-
lasts acquire alpha smooth muscle actin expression during
bleomycin-induced pulmonary fibrosis. Am J Pathol
143:1754-1765 (1993).
87. Goldstein RH, Fine A. Fibrotic reactions in the lung: the activa-
tion ofthe lung fibroblast. Exp Lung Res 11:245-261 (1986).
88. Raines EW, Dower SK, Ross R. lnterleukin-1 mitogenic activity
for fibroblasts and smooth muscle cells is due to PDGF-AA.
Science 243:393-395 (1989).
89. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF, Ross R.
TGF-beta induces bimodal proliferation of connective tissue
cells via complex control of an autocrine PDGF-loop. Cell
63:515-524 (1990).
90. Okazaki H, Majesky MW, Harker LA, Schwartz SM. Regulation
of platelet-derived growth factor ligand and receptor gene
expression by alpha-thrombin in vascular smooth muscle cells.
Circ Res 71:1285-1293(1992).
91. Ross R, GlomsetJA, Kariya B, Harker L. A platelet-derived serum
factor that stimulates the proliferation of arterial smooth muscle
cells in vitro. Proc NatI Acad Sci USA 71:1207-1210(1974).
92. Raines E. Peptide Growth Factors and Their Receptors. New
York:Springer-Verlag, 1991.
93. Larsson D, Latham C, Zickert P, Zetterberg A. Cell cycle regula-
tion of human diploid fibroblasts: possible mechanisms of
platelet-derived growth factor. J Cell Physiol 139:477-483
(1989).
94. Hart CE, Forstrom JW, Kelly JD, Seifert RA, Smith RA, Ross
R, Murray MJ, Bowen-Pope DF. Two classes of PDGF recep-
tor recognize different isoforms of PDGF. Science
240(4858(:1529-1531 (1988).
95. Heldin C-H, Westermark B. Signal transduction bythe receptors
for platelet-derived growth factor. Science 96:193-196 (1990).
96. Seifert RA, Coats SA, Raines EW, Ross R, Bowen-Pope DF.
Platelet-derived growth factor (PDGF) receptor alpha-subunit
mutant and reconstituted cell lines demonstrate that transform-
ing growth factor-beta can be mitogenic through PDGF A-chain-
dependent and -independent pathways. J Biol Chem
269:13951-13955 (1989).
97. Oefner C, D'ArcyA, Winkler FK, Eggimann B, Hosang M. Crystal
structure of human platelet-derived growth factor BB. EMBO J
11(11:3921-3926 (1992).
98. Rosenfeld ME, Bowen-Pope DF, Ross R. Platelet-derived growth
factor: morphologic and biochemical studies of binding internal-
ization, and degradation. J Cell Physiol 121:263-274(1984).
99. Tsukamoto T, Matsui T, Nakata H, Ito M, Natazuka T, Fukase
M, Fujita T. lnterleukin-1 enhances the response of osteoblasts
to platelet-derived growth factor through the alpha receptor-
specific up-regulation. J Biol Chem 266:10143-10147 (1991).
100. Majack RA, Majesky MW, Goodman LV. Role of PDGF-A
expression in the control of vascular smooth muscle cell growth
by transforming growth factor-beta. J Cell Biol 111:239-247
(1990).
101. Ishikawa 0, LeRoy EC, Trojanowska M. Mitogenic effect of
transforming growth factor beta-1 on human fibroblasts
involves the induction of platelet-derived growth factor alpha
receptors. J Cell Physiol 145:181-186 (1990).
102. Tani K, Ogushi F, Takahashi H, Kawano T, Endo T, Sone S.
Thrombin stimulates platelet-derived growth factor release by
alveolar macrophages in rats-significance in bleomycin-induced
pulmonary fibrosis. J Med Invest 44(1-2):59-65 (1997).
103. Battegay EJ, Raines EW, Cobert T, Ross R. TNF- Stimulation of
fibrobalst proliferation. Dependence on platelet-derived growth
factor (PDGF) secretion and alteration of PDGF receptor expres-
sion. J Immunol 154:6040-6047 (1995).
104. Schollmann C, Grugel R, Tatje D, Hoppe J, Folkman J, Marme
D, Weich H. Basic fibroblast growth factor modulates the mito-
genic potency of the platelet-derived growth factor isoforms by
specific upregulation of the PDGF alpha receptor in vascular
smooth muscle cells. J Biol Chem 267:18032-18039 (1992).
105. BonnerJC, Goodell AL, LaskyJA, Hoffman MR. Reversible bind-
ing of platelet-derived growth factor-AA, -AB, and -BB isoforms
to a similar site on the "slow" and "fast" conformations of
alpha-2-macroglobulin. J Biol Chem 267:12837-12844 (1992).
106. Heldin C-H, Johnsson A, Wennergren S, Wernstadt C,
Betscholtz C, Westermark B. A human osteosarcoma cell line
secretes a growth factor structurally related to a homodimer of
PDGF-A chains. Nature 315:511-514 (1986).
107. Abboud HE, Poptic E, DiCorletto P. Production of platelet-
derived growth factor-like protein by rat mesangial cells in cul-
ture. J Clin Invest80:675-683 (1988).
108. Majesky MW, Benditt EP, Schwartz SM. Expression and devel-
opmental control of platelet-derived growth factor A-chain and
B-chain/sis genes in rat aortic smooth muscle cells. Proc NatI
Acad Sci USA 85:1524-1528 (1988).
109. Strurani E, Brambilla R, Morello L, Cattaneo MG, Zippel R,
Alberghina L. Effect of the different dimeric forms of the
platelet-derived growth factor on cellular responses in mouse
Swiss3T3fibroblasts. FEBS Lett255:191-195 (1989).
110. Chen B, Pounovsky V, White J, Blazar B, Nakhleh R, Jessurun J,
Peterson M, Bitterman P. Mesenchymal cells isolated after
acute lung injury manifest an enhanced proliferative phenotype.
J Clin Invest 90:1778-1785 (1992).
111. Bishop JE, Butt RP, Cambrey AD, Laurent GJ. Mechanical force
stimulates the release of PDGF by fibroblasts [Abstract]. Cell
Biol 100:242a (1989).
112. Martinet Y, Rom WN, Grotendorst GR, Martin GR, Crystal RG.
Exagerated sponataneous release of platelet-derived growth
factor by alveolar macrophages from patients with idiopathic
pulmonary fibrosis. N EngI J Med 317:202-209 (1987).
113. Antoniades HN, Bravo MA, Avila RE, Galanopoulos T, Neville-
Golden J, Selman M. Platelet-derived growth factor in idio-
pathic pulmonary fibrosis. J Clin Invest 86:1055-1064 (1990).
114. Vignaud JM, Allam M, Martinet M, Pech M, Plenat F, Martinet
Y. Presence of platelet-derived growth factor in normal and
fibrotic lung is associated with interstitial macrophages, while
both interstitial macrophages and alveolar epithelial cells
express the c-sis proto-oncogene. Am J Respir Cell Mol Biol
5:531-538 (1991).
115. Nagaoka I, Trapnell BC, Crystal RG. Upregulation of platelet-
derived growth factor-A and -B gene expression in alveolar
macrophages of individuals with idiopathic pulmonary fibrosis.
J Clin Invest 85:2023-2027 (1990).
116. Homma S, Nagaoka I, Abe H, Takahashi K, Seyama K, Nukiwa
T, Kira S. Localization of platelet-derived growth factor and
insulin-like growth factor in the fibrotic lung. Am J Respir Crit
Care Med 152:2084-2089 (1995).
117. Deguchi Y, Kishimoto S. Enhancement of C-sis protoconcogene
transcription in broncoalveolar mononuclear cells from patients
with autoimmune diseases with lung involvement. Bioch
Biophys Res Commun 164:1018-1024 (1989).
118. Ludwicka A, Ohba T, Trojanowska M, Yamakage A, Strange C,
Smith EA, Leroy EC, Sutherland S, Silver RM. Elevated levels of
platelet derived growth factor and transforming growth factor-
beta 1 in bronchoalveolar lavage fluid from patients with sclero-
derma. J Rheumatol 22(10):1876-1883 (1995).
119. Snyder LS, Hertz Ml, Peterson MS, Harmon KR, Marinelli WA,
Henke CA, Greenheck JR, Chen B, Bitterman PB. Acute lung
injury: pathogenesis of intraalveolar fibrosis. J Clin Invest
88:663-673 (1991).
120. Barth J, Kreipe H, Radzun HJ, Heidorn K, Peterman W, Bewig B,
Parwaresch MR. Increased expression of growth factor genes
for macrophages and fibrobalsts in bronchoalveolar lavage cells
of a patient with pulmonary histiocytosis X. Thorax 46:835-838
(1991).
121. Hertz Ml, Henke CA, Nakhleh RE, Harmon KR, Marinelli WA,
Fox JMK, Kubo SH, Shumway SJ, Bolman RM, Bitterman PB.
Obliterative bronchiolitis after lung transplantation: a fibropro-
liferative disorder associated with platelet-derived growth fac-
tor. Proc Natl Acad Sci USA 89:10385-10389(1992).
122. Limper AH, Broekelmann TJ, Colby TV, Malizia G, McDonald
JA. Analysis of local mRNA expression for extracellular matrix
proteins and growth factors using in situ hybridization in fibro-
proliferative disorders. Chest99:55-56S (1991).
123. Facon T, Goodemand J., Cavon C, Zandecki M, Estienne MH,
Fenaux P, Cosson A. Simultaneous occurrence of grey platelet-
syndrome and idiopathic pulmonary fibrosis: a role for abnormal
megakaryocytes in the pathogenesis of pulmonary fibrosis. Br J
Haemetol 74(4):542-543 (1990).
124. Antoniades HN. Linking cellular injury to gene expression and
human proliferative disorders: examples with the PDGF genes.
Mol Carcinog 6:175-181 (1992).
125. Okano A, Sato A, Chida K, Hayakawa H, Iwata M, Yasuda K,
Shichi I, Suda T, Maeda T. Pulmonary interstitial pneumonia in
association with Hermansky-Pudlak syndrome. Jap J Thoracic
Dis 29:1596-1602 (1991).
126. Lasky JA, JC Bonner, B Tonthat, AR Brody. Chrysotile asbestos
induces PDGF-A chain-dependent proliferation in human and
rat lung fibroblasts in vitro. Chest 109:26S-28S (1996).
127. Fabisiak JP, Evans JN, Kelley J. Increased expression of PDGF-
B (c-cis) mRNA in rat lung precedes DNA synthesis and tissue
repair during chronic hyperoxia. Am J Respir Cell Mol Biol
1:181-189 (1989).
128. Fabisiak JP, Evans JN, Abscher M, Gannon D, Kelley J.
Expression of platelet-derived growth factor A-chain mRNA in
lung tissue and cells. Chest 99:52-54S (1991).
129. Lindroos PM, Coin PG, Badgett A, Morgan DL, Bonner JC.
Alveolar macrophages stimulated with titanium dioxide, chryso-
tie asbestos, and residual oil fly ash upregulate the PDGF recep-
tor-alpha on lung fibroblasts through an IL-lbeta-dependent
mechanism. Am J Respir Cell Mol Biol 16(3):283-292 (1997).
130. Lindroos PM, Coin PG, Osornio-Vargas AR, Bonner JC.
Interleukin 1 beta and the IL-1 beta-alpha-2-macroglobulin com-
plex upregulate the platelet-derived growth factor alpha-recep-
tor on rat pulmonary fibroblasts. Am J Respir Cell Mol Biol
13:455-465(1995).
131. Dai J, Gilks B, Price K, Churg A. Mineral dusts directly induce
epithelial and interstitial fibrogenic mediators and matrix com-
ponents in the airway wall. Am J Respir Crit Care Med
158(6):1907-1913 (1998).
132. Brody AR, Bonner JC, Overby LH, Badgett A, Kalter V, Kumar
RK, Bennett RA. Interstitial pulmonary macrophages produce
platelet-derived growth factorthat stimulates rat lung fibroblast
proliferation in vitro. J Leukoc Biol 51:640-648 (1992).
133. Roggli VL, Greenberg SD, Pratt PC. Pathology of Asbestos-
Related Diseases, 1st ed. Boston/Toronto/London:Little, Brown
and Company, 1992.
134. Bonner JC, Osornio-Vargas AR, Badgett A, Brody AR.
Differential proliferation of rat lung fibroblasts induced by the
platelet-derived growth factor-AA, -AB and -BB isoforms
secreted by rat alveolar macrophages. Am J Respir Cell Mol
Biol 5(6):539-547 (1991).
135. Hoyle GW, Li J, Finkelstein JB, Eisenberg T, Liu JY, Lasky JA,
Athas G, Morris GF, Brody AR. Emphysematous lesions, inflam-
mation, and fibrosis in the lungs of transgenic mice overex-
pressing platelet-derived growth factor. Am J Pathol
154)6):1763-1775 (1999).
136. Yoshida M, Hayashi S. Role of TGF-beta and PDGF on the
pathogenesis of pulmonary fibrosis-analysis by in vivo gene
transfer. Nippon Rinsho 54(2):418-422(1996).
137. Yi ES, Lee H, Yin S, Piguet P, Sarosi I, Kaufmann S, Tarpley J,
Wang NS, Ulich TR. Platelet-derived growth factor causes pul-
monary cell proliferation and collagen deposition in vivo. Am J
Pathol 149(2):539-548 (1996).
138. Banai S, WolfY, Golomb G, Pearle A, WaltenbergerJ, Fishbein I,
Schneider A, GazitA, Perez L, Huber R, et al. PDGF-receptor tyro-
sine kinase blocker AG1295 selectively attenuates smooth mus-
cle cell growth in vitro and reduces neointimal formation after
balloon angioplasty in swine. Circulation 97:1960-1969 (1998).
139. Rice AB, Moomaw CR, Morgan DL, Bonner JC. Specific
inhibitors of platelet-derived growth factor or epidermal growth
factor receptor tyrosine kinase reduce pulmonary fibrosis in
rats. Am J Pathol J1)55(1:213-221 (1999).
140. Kallio E, Koskinen P, Buchdunger E, Lemstrom K. Inhibition of
obliterative bronchiolitis by platelet-derived growth factor
receptor protein-tyrosine kinase inhibitor. Transplant Proc
31)1-2):187-196 (1999).
141. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits
PDGF isoforms in bleomycin hamster model of lung fibrosis at
the translational level. Am J Physiol 276 (2, Pt 1):L311-L318
(1999).
142. Bostrum H, Willetts K, Pekny M, Leveen P, Lindahl P, Hedstrand
H, Pekna M, Heilstrom H, Gebre-Medhin 5, Schalling M, et al.
PDGF-A signaling is a critical event in lung alveolar myofibrob-
last development and alveogenesis. Cell 58:863-876 (1996).
Environmental Health Perspectives * Vol 108, Supplement 4 * August 2000 761LASKY AND BRODY
143. Lindahl P, Karlsson M, Gebre-Medhin S, Willetts K, Heath JK,
Betsholtz C. Alveogenesis failure in PDGF-A-deficient mice is
coupled to the lack of distal spreading of alveolar smooth mus-
cle cell progenators during lung development. Development
124:3943-3952 (1997).
144. Leveen P, Pekny M, Gebre-Medhin S, Swolin B, Larsson E,
Betshortz C. Mice deficient for PDGF B show renal, cardiovascu-
lar, and hematological abnormalities. Genes Dev
8(16):1875-1887 (1994).
145. Crosby JR, Tappan Kam, Seifert RA, Bowen-Pope DF. Chimera
analysis reveals that fibroblasts and endothelial cells require
platelet-derived growth factor receptor beta expression for
participation in reactive connective tissue formation in adults
but not during development. Am J Pathol 154(5):1315-1321
(1999).
146. Roberts AB, Sporn MB, ed. The transforming growth factor
betas. In: Peptide Growth Factors and Their Receptors,
Handbook of Experimental Pharmacology. Berlin:Springer-
Verlag, 1990;419-472.
147. Coker RK, laurent GJ, Shahzeidi S, Lympany PA, duBois RM,
Jeffery PK, McAnujity RJ. Transforming growth factors-beta 1,
-beta 2, and -beta 3 stimulate fibroblast procollagen production
in vitro but are differentially expressed during bleomycin-
induced lung fibrosis. AmJ Pathol 150)3):981-991 (1997).
148. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, lawler
J, Hynes RO, Boivin GP, Bouck N. Thrombospondin-1 is a major
activator ofTGF-betal invivo. Cell 93(7):1159-1170 (1998).
149. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL,
Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, et al. The
integrin alpha v beta 6 binds and activates latentTGF beta 1: a
mechanism for regulating pulmonary inflammation and fibrosis.
Cell 96(3):319-328 (1999).
150. Ebner R, Chen RH, Shum L, Lawler S, Zioncheck TF, Lee A,
Lopez AR, Derynck R. Cloning of a type TGF-beta receptor and
its effect on TGF-beta binding to the type 11 receptor. Science
260(5112):1344-1348(1993).
151. Zhao Y, Gilmore BJ, Young SL. Expression of transforming
growth factor-beta receptors during hyperoxia-induced lung
injuryand repair. AmJ Physiol 273(2, Pt 1):L355-362 (1997).
152. Dore JJ Jr, Edens M, Garamszegi N, Leof EB. Heteromeric and
homomeric transforming growth factor-beta receptors show
distinct signaling and endocytic responses in epithelial cells. J
Biol Chem 273(48(:31770-31777 (1998).
153. Yamamoto H, Ueno H, Ooshima A, Takeshita A. Adenovirus-
mediated transfer of a truncated transforming growth factor-
beta (TGF-beta) type 11 receptor completely and specifically
abolishes diverse signaling byTGF-beta in vascular wall cells in
primaryculture. J Biol Chem 271(27):16253-16259 (1996).
154. Zhao J, Sime PJ, Bringas P Jr, Gauldie J, Warburton D.
Epithelium-specific adenoviral transfer of a dominant-negative
mutant TGF-beta type 11 receptor stimulates embryonic lung
branching morphogenesis in culture and potentiates EGF and
PDGF-AA. Mech Dev7211-2):89-100 (1998).
155. Asakura S, Kato H, Fukino S, Konishi T, Tezuka N, Mori A. Role
of transforming growth factor-betal and decorin in develop-
ment of central fibrosis in pulmonary adenocarcinoma. Hum
Pathol 3012):195-198 (1999).
156. BonnerJC, Brody AR. Cytokine-binding proteins in the lung. Am
J Physiol 268(6 Pt 1):L869-L878 (1995).
157. Giri SN, Hyde DM, Braun RK, Gaarde W, Harper JR,
Pierschbacher MD. Antifibrotic effect of decorin in a bleomycin
hamster model of lung fibrosis. Biochem Pharmacol
54(11):1205-1216(1997).
158. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M,
Allen R, Sidman C, Proetzel G, Calvin D, et al. Targeted disrup-
tion of the mouse transforming growth factor-beta 1 gene
results in multifocal inflammatory disease. Nature
;35916397):693-699 (1992).
159, Leof EB, Proper JA, Goustin AS, Shipley GD, DiCorleto Pe,
Moses HC. Induction of c-sis mRNA and activity similar to
platelet-derived growth factor by transforming growth factor
beta: a proposed model for indirect mitogenesis involving
autocrineactivity. Proc NatIAcad Sci USA83:2453-57 (1986).
160. Fine A, Goldstein RH. The effect of transforming growth factor-
,B on cell proliferation and collagen formation by lung fibrob-
lasts. J Biol Chem262(8):3897-3902 (1987).
161. Bienkowski RS, Gotkin, MG. Control of Collagen Deposition in
Mammalian Lung. Proc Soc Exp Biol Med 209:118-140 (1995).
162. Khalil N, O'Connor RN, Flanders KC, Shing W, Whitman Cl.
Regulation of type 11 alveolar epithelial cell proliferation by
TGF-beta during bleomycin-induced lung injury in rats. Am J
Physiol 267:L498-507 (1994).
163. Seifert RA, Coats SA, Raines EW, Ross R, Bowen-Pope DF.
Platelet-derived growth factor (PDGF) receptor alpha-subunit
mutant and reconstituted cell lines demonstrate that transform-
ing growth factor-beta can be mitogenic through PDGF A-chain-
dependent and -independent pathways. J Biol Chem
269:13951-13955 (1994).
164. Kalter VG, Brody AR. Receptors for transforming growth factor
,B (TGF) on rat lung fibroblasts have higher affinity for TGF,B1
than forTGFB2. Am J Respir Cell Mol Biol 4:397-407 (1991).
165. Krupsky M, Fine A, Kuang PP, Berk JL, Goldstein RH. Regulation
oftype collagen production by insulin and transforming growth
factor-beta in human lung fibroblasts. Connect Tissue Res
34(1):53-62 (1996).
166. Agarwal AR, Goldstein RH, Lucey E, Ngo HQ, Smith BD. Cell-
specific expression of the alpha 1 (I) collagen promoter-CAT
transgene in skin and lung: a response to TGF-beta subcuta-
neous injection and bleomycin endotracheal instillation. J Cell
Biochem 63(2):135-48 (1996).
167. McAnulty RJ, Campa JS, Cambrey AD, Laurent GJ. The effect
of transforming growth factor beta on rates of procollagen syn-
thesis and degradation in vitro. Biochim Biophys Acta
1091(2):231-5 (1991).
168. Moller DR. Cells and cytokines involved in the pathogenesis of
sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis16(1):24-31
(1999).
169. Eickelberg 0, Kohler E, Reichenberger F, Bertschin S, Woodtli T,
Erne P, Perruchoud AP, Roth M. Extracellualr matrix deposition
by primary human lung fibroblasts in response to TGF-betal and
TGF-beta3. Am J Physiol 276(5, Pt 1):L814-L824 (1999).
170. Jagirdar J, Lee TC, Reibman J, Gold LI, Aston C, Begin R, Rom
WN. Immunohistochemical localization of transforming growth
factor beta isoforms in asbestos-related diseases. Environ
Health Perspect 105 Suppl 5:1197-1203 (1997).
171. Jagirdar J, Begin R, Dufresne A, Goswami S, Lee TC, Rom WN.
Transforming growth factor-beta (TGF-beta) in silicosis. Am J
Respir Crit Care Med 154:1076-1081 (1996).
172. Limper AH, Colby TV, Sanders MS, Asakura S, Roche PC,
DeRemee RA. Immunohistochemical localization of transform-
ing growth factor-beta 1 in the nonnecrotizing granulomas of
pulmonary sarcoidosis. Am J Respir Crit Care Med
149(1(:197-204 (1994).
173. Broekelmann TJ, Limper AH, Colby TV, McDonald JA.
Transforming growth factor beta 1 is present at sites of extra-
cellular matrix gene expression in human pulmonary fibrosis.
Proc NatI Acad Sci USA88(15):6642-6646(1991).
174. Salez F, Gosset P, Copin MC, Lamblin Degros C, Tonnel AB,
Wallaert B. Transforming growth factor-betal in sarcoidosis.
Eur RespirJ 12(4):913-919 (1998).
175. Asakura S, Colby TV, Limper AH. Tissue localization of trans-
forming growth factor-betal in pulmonary eosinophilic granu-
loma. Am J Respir Crit Care Med 154(5):1525-1530 (1996).
176. Khalil N, Corne S, Whitman C, Yacyshyn H. Plasmin regulates
the activation of cell-associated latent TGF-beta 1 secreted by
rat alveolar macrophages after in vivo bleomycin injury. Am J
Respir Cell Mol Biol 15(2):252-259 (1996).
177. Hiwatari N, Shimura S, Yamauchi K, Nara M, Hida W, Shirato
K. Significance of elevated procollagen-Ilil-peptide and trans-
forming growth factor-beta levels of bronchoalveolar lavage flu-
ids from idiopathic pulmonary fibrosis patients. Tohoku J Exp
Med 181(2):285-295 (1997).
178. Heine U, Munoz EF, Flanders KC, Roberts AB, Sporn MB.
Colocalization of TGF-beta 1 and collagen and Ill, fibronectin
and glycosaminoglycans during lung branching morphogenesis.
Development 109(1):29-36 (1990).
179. Hoyt DG, Lazo JS. Alterations in pulmonary mRNA encoding
procollagens, fibronectin and transforming growth factor-beta
precede bleomycin-induced pulmonary fibrosis in mice. J
Pharmacol Exp Ther246(2):765-71 (1988).
180. Perdue TD, Brody AR. Distribution of transforming growth
factor-beta 1, fhbronectin, and smooth muscle actin in asbestos-
induced pulmonary fibrosis in rats. J Histochem Cytochem
42(8(:1061-1070(1994).
181. Franko AJ, Sharplin J, Ghahary A, Barcellos-Hoff MH.
Immunohistochemical localization of transforming growth factor
beta and tumor necrosis factor alpha in the lungs of fibrosis-
prone and "non-fibrosing` mice during the latent period and early
phase after irradiation. Radiat Res 147(2):245-256 (1997).
182. Hagimoto N, Kuwano K, Miyazaki H, Kunitake R, Fujita M,
Kawasaki M, Kaneko Y, Hara N. Induction of apoptosis and pul-
monary fibrosis in mice in response to ligation of Fas antigen.
Am J Respir Cell Mol Biol 17(3):272-278 (1997).
183. Girn SN, Hyde DM, Hollinger MA. Effect of antibody to trans-
forming growth factor beta on bleomycin induced accumulation
of lung collagen in mice. Thorax48(10):959-966 (1993).
184. Li J, He B, Weng B. The therapeutic effect of TGF-beta mono-
cional antibody to bleomycin-induced pulmonary fibrosis in rats.
Chung Hua Chich Ho Ho Hu His Tsa Chih 20(6):347-349 (1997).
185. Wang Q, Wang Y, Hyde DM, Gotwals PJ, Koteliansky VE, Ryan
ST, Giri SN. Reduction of bleomycin induced lung fibrosis by
transforming growth factor beta soluble receptor in hamsters.
Thorax 54(9):805-812 (1999).
186. Lee TC, Gold LI, Reibman J, Aston C, Begin R, Rom WN,
Jagirdar J. Immunohistochemical localization of transforming
growth factor-beta and insulin-like growth factor-1 in asbesto-
sis in the sheep model. lnt Arch Occup Environ Health
69(3):157-164 (1997).
187. Mariani TJ, Roby JD, Mecham RP, Parks WC, Crouch E, Pierce
RA. Localization of type procollagen gene expression in silica-
induced granulomatous lung disease and implication of trans-
forming growth factor-beta as a mediator of fibrosis. Am J
Pathol 148(1):151-164 (1996).
188. Gauldie J, Sime PJ, Xing Z, Marr B, Tremblay GM. Transforming
growth factor-beta gene transfer to the lung induces myofibrob-
last presence and pulmonary fibrosis. Curr Top Pathol 93:35-45
(1999).
189. Burger A, Loffler H, Bamberg M, Rodemann HP. Molecular and
cellular basis of radiation fibrosis. Int J Radiat Biol
73(4(:401-408 (1998).
190. Piguet PF, Van GY, Guo J. Heparin attenuates bleomycin but not
silica-induced pulmonary fibrosis in mice: possible relationship
with involvement of myofibroblasts in bleomycin, and fibrob-
lasts in silica-induced fibrosis. Int J Exp Pathol 77(4):155-161
(1996).
191. Yoshida M, Sakuma J, Hayashi S, Abe K, Saito I, Harada S,
Sakatani M, Yamamoto S, Matumoto N, Kaneda Y. A histologi-
cally distinctive interstitial pneumonia induced by overexpres-
sion of the interleukin 6, transforming growth factor beta 1, or
platelet-derived growth factor B gene. Proc NatI Acad Sci USA
92(21:9570-9574(1995).
192. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-
mediated gene transfer of active transforming growth factor-
betal induces prolonged severe fibrosis in rat lung. J Clin Invest
100(4(:768-776 (1997).
193. Kaartinen V, Voncken JW, Shuler C, Warburton D, Bu D,
Heisterkamp N, Groffen J. Abnormal lung development and
cleft palate in mice lacking TGF-beta 3 indicates defects of
epithelial-mesenchymal interaction. Nat Genet 11(4):415-421
(1995).
194. Bottinger EP, Jakubczak JL, Haines DC, Bagnall K, Wakefield
LM. Transgenic mice overexpressing a dominant-negative
mutant type 11 transforming growth factor beta receptor show
enhanced tumorigenesis in the mammary gland and lung in
response to the carcinogen 7,12-dimethylbenz-[al-anthracene.
Cancer Res 57(24):5564-5470(1997).
195. Unemori EN, Pickford LB, Salles AL, Piercy CE, Grove BH,
Erikson ME, Amento EP. Relaxin induces an extracellular
matrix-degrading phenotype in human lung fibroblasts in vitro
and inhibits lung fibrosis in a murine model in vivo. J Clin Invest
98(12):2739-2745 (1996).
196. Matrat M, Lardot C, Huaux F, Broeckaert F, Lison D. Role of
urokinase in the activation of macrophage-associated TGF-beta
in silica-induced lung fibrosis. J Toxicol Environ Health
55(5):359-371 (1998).
197. Grotendorst GR. Connective tissue growth factor: a mediator of
TGF-beta action on fibroblasts. Cytokine Growth Factor Rev
8(3(:171-179 (1997).
198. Frazier K, Williams S, Kothapalli D, Klapper H, Grotendorst GR.
Stimulation of fibroblast cell growth, matrix production, and
granulation tissue formation by connective tissue growth factor.
J Invest Dermatol 107(3):404-41 1 (1996).
199. Huang SS, Liu Q, Johnson FE, Konish Y, Huang JS. Transforming
growth factor beta peptide antagonists and their conversion to
partial agonists. J Biol Chem272(43):27155-27159 (1997).
200. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ,
Hutchinson IV. Genotypic variation in the transforming growth
factor-betal: association with transforming growth factor-betal
production, fibrotic lung disease, and graft fibrosis after lung
transplantation. Transplantation 66(8):1014-1020(1998).
762 Environmental Health Perspectives * Vol 108, Supplement4 * August 2000